

Curriculum Vitae

Peter Vadas
MD, PhD, FRCPC, FACP

A. Date Curriculum Vitae is Prepared: August 12, 2013

B. Biographical Information

| | |
|----------------|---|
| Primary Office | Division of Clinical Immunology, Department of Medicine 8th Floor Carter Wing, Room 8-161 St. Michael's Hospital 30 Bond Street Toronto, Ontario M5B 1W8 |
| Telephone | [416] 864-5777 |
| Fax | [416] 864-3033 |
| Email | vadasp@smh.ca |

1. EDUCATION

Degrees

| | |
|-----------------|--|
| 1980 - 1983 Jun | MD, Faculty of Medicine, University of Toronto, Toronto, Ontario |
| 1978 - 1980 | PhD, Department of Pathology, University of Toronto, Toronto, Ontario |
| 1976 - 1978 | MSc, (waived) Department of Pathology, University of Toronto, Toronto, Ontario |
| 1972 - 1976 | Hons. BSc, Biochemistry, University of Toronto, Toronto, Ontario |

Postgraduate, Research and Specialty Training

| | |
|-------------|---|
| 1989 - 1990 | Fellow, Clinical Immunology and Allergy, Department of Medicine, University of Toronto |
| 1986 - 1989 | Resident, Internal Medicine, Department of Medicine, University of Toronto |
| 1984 - 1986 | MRC Post-Doctoral Fellow, Division of Immunology, Department of Medicine, Wellesley Hospital, Toronto |
| 1983 - 1984 | Mixed Internship, Mount Sinai Hospital, Toronto |

Qualifications, Certifications and Licenses

| | |
|------|--|
| 1992 | Fellow, American College of Physicians |
| 1992 | Fellow, Canadian Society for Allergy and Clinical Immunology |
| 1990 | Fellow, Internal Medicine, Royal College of Physicians of Canada |
| 1990 | Fellow, Clinical Immunology and Allergy, Royal College of Physicians of Canada |
| 1990 | Specialist Certification, Internal Medicine, Canada |
| 1990 | Specialist Certification, Clinical Immunology and Allergy, Canada |
| 1989 | Diplomate, American board of Internal Medicine |
| 1989 | Specialist Certification, Internal Medicine, United States |
| 1983 | Licentiate, Medical Council of Canada, Ontario |

2. EMPLOYMENT

Current Appointments

| | |
|----------------|---|
| 2002 - present | Senior Scientist, Li Ka Shing Research Institute |
| 1998 - present | Staff Physician, Division of Allergy and Clinical Immunology, St. Michael's Hospital |
| 1998 - present | Director, Division of Allergy and Clinical Immunology, Department of Medicine, St. Michael's Hospital |
| 1997 - present | Associate Professor, Department of Medicine, Faculty of Medicine, University of Toronto |
| 1992 - present | Assistant Professor, Department of Immunology, Faculty of Medicine, University of Toronto |
| 1992 - present | Associate Member, Institute of Medical Science, University of Toronto |

Previous Appointments

CLINICAL

| | |
|-------------|--|
| 1990 - 1998 | Staff Physician, Divisions of Allergy and Clinical Immunology and General Internal Medicine, The Wellesley Hospital, Toronto |
| 1984 - 1986 | Staff Physician, Department of Emergency Medicine, Toronto East General Hospital, Toronto |
| 1984 - 1985 | Staff Physician, Department of Emergency Medicine, Doctor's Hospital, Toronto |

HOSPITAL

| | |
|-------------|--|
| 1993 - 1996 | Director, Postgraduate Medical Education, Department of Medicine, Wellesley Hospital |
|-------------|--|

RESEARCH

| | |
|-------------|---|
| 1986 - 1988 | Consultant, California Biotechnology Inc. Mountain View, California |
| 1980 - 1983 | Medical Scientist, Canadian Heart Foundation |

UNIVERSITY

| | |
|-------------|---|
| 1992 - 1997 | Assistant Professor, Division of Immunology, Department of Medicine, Faculty of Medicine, University of Toronto |
| 1987 - 1992 | Lecturer, Department of Medicine, University of Toronto |
| 1982 - 1987 | Research Associate, Department of Medicine, University of Toronto |

UNIVERSITY - CROSS APPOINTMENT

| | |
|-------------|--|
| 1990 - 1995 | Lecturer, Department of Pathology, University of Toronto |
|-------------|--|

3. HONOURS AND CAREER AWARDS

Distinctions and Research Awards

Received

| | |
|----------------|---|
| 2009 | Distinguished Researcher of the Year , Canadian Society of Allergy and Clinical Immunology. Canada. (Distinction) <i>Award given to outstanding researcher of the year.</i> |
| 2002 - 2003 | National Register's Who's Who in Executives and Professionals. (Distinction) <i>Biographical Entry.</i> |
| 2001 | David McCourtie Memorial Lectureship , Canadian Society of Allergy and Clinical Immunology, Annual Meeting. (Distinction) |
| 1992 - present | Canadian Who's Who. (Distinction) <i>Biographical Entry.</i> |
| 1992 - present | Men of Achievement. (Distinction) <i>Biographical Entry.</i> |
| 1991 - present | Dictionary of International Biography. (Distinction) |

| | |
|----------------|---|
| | Biographical Entry. |
| 1991 - present | Directory of Medical Specialists. (Distinction) Biographical Entry. |
| 1991 - present | International Who's Who of Intellectuals. (Distinction) Biographical Entry. |
| 1990 - present | American Men and Women of Science. (Distinction) Biographical Entry. |
| 1991 - 1996 | Career Scholarship, Medical Research Council. (Distinction) |
| 1987 | F.M. Hill Research Award. (Distinction) |
| 1984 - 1986 | Post-Doctoral Fellowship, Medical Research Council. (Distinction) |
| 1982 | Walter F. Watkins Scholarship. (Distinction) |
| 1981 - 1983 | Samuel Castrilli Award. (Distinction) |
| 1980 - 1981 | Ontario-Quebec Exchange Fellowship. (Distinction) |
| 1979 - 1980 | Health Sciences Committee Award. (Distinction) |
| 1979 | Chisholm Memorial Fellowship. (Distinction) |
| 1978 - 1979 | Doctoral Open Fellowship, University of Toronto. (Distinction) |
| 1976 - 1978 | Masters Open Fellowship, University of Toronto. (Distinction) |
| 1976 - 1977 | Summer Scholarship, Health Sciences Committee. (Distinction) |
| 1972 | Ontario Scholar. (Distinction) |

4. PROFESSIONAL AFFILIATIONS AND ACTIVITIES

Professional Associations

| | |
|----------------|---|
| 2006 - 2009 | Member, Board of Consultants, The Canadian Journal of CME |
| 2002 - present | Member, Peanut Bureau of Canada |
| 2001 - 2003 | Chair, Anaphylaxis Committee, American Academy of Allergy, Asthma and Immunology |
| 2000 - 2007 | Co-Chair, OMA Section of Allergy and Immunology |
| 1999 - 2005 | Member, Board of Examiners for Allergy and Clinical Immunology, Royal College of Physicians and Surgeons of Canada |
| 1999 - 2003 | Head, Section of Anaphylaxis, Canadian Society of Allergy and Clinical Immunology |
| 1999 - 2002 | Representative for Allergy and Clinical Immunology, Resource-Based Relative Value Schedule Commission |
| 1999 - 2001 | Vice-Chair, Anaphylaxis Committee, American Academy of Allergy, Asthma and Immunology |
| 1999 - present | Member, Executive Committee, Allergy, Asthma and Immunology Society of Ontario |
| 1997 - 2002 | Member, Nucleus Committee in Clinical Immunology and Allergy, The Royal College of Physicians and Surgeons of Canada |
| 1996 - 2000 | President, Anaphylaxis Foundation of Canada |
| 1991 - 2007 | Member, Board of Directors, Canadian Society for Allergy and Clinical Immunology |
| 1991 - 2005 | Member, Steering Committee, International Association of Inflammation Societies |
| 1991 - 1996 | Member, Shock Society |
| 1991 - 1994 | Member, Ontario Allergy Society, Human Ethics Committee |
| 1990 - 1994 | Member, New York Academy of Sciences |
| 1987 - 1991 | Member, American College of Rheumatology |
| 1984 - 2000 | Member, Canadian Society for Clinical Investigation |
| 1983 - present | Member, Ontario Medical Association |
| 1983 - present | Member, Royal College of Physicians and Surgeons |
| 1981 - 2000 | Member, Inflammation Research Association |

1980 - 1991 **Member**, Canadian Society of Immunology

Administrative Activities

NATIONAL

Allergy Asthma Information Association

1996 - present **Member**, Medical Advisory Committee, Allergy Asthma Information Association

Anaphylaxis Canada

2000 - present **Member**, Medical Advisory Committee, Anaphylaxis Canada

Canadian Society of Allergy and Clinical Immunology

1996 - 2000 **Chair**, Anaphylaxis Registry and Database, Canadian Society of Allergy and Clinical Immunology

PROVINCIAL / REGIONAL

Allergy Asthma Immunology Society of Ontario

1999 - present **Member**, Executive Committee, Allergy Asthma Immunology Society of Ontario, Ontario, Canada.

LOCAL

Other Organizations

1992 **Consultant**, Independent Advisory Committee on Silicone Gel-filled Implants
University of Toronto.

1988 - 1998 **Deputy Director**, Inflammation Research Group
University of Toronto

Ewart Angus Intensive Care Unit

1990 - 1996 **Member**, Research Committee,
Wellesley Hospital.

St. Michael's Hospital

1998 - present **Member**, Division Heads Committee, Department of Medicine
St. Michael's Hospital.

1998 – present *Member, Specialized Complex Care Committee, St. Michael's Hospital*

1998 - present **Director**, Division of Allergy and Clinical Immunology
Hospital.

1998 - 2000 **Member**, Inner City Health Management Advisory Team
Hospital.

The Toronto Hospital, General Division

1994 **Member**, On-Site Review Committee
University of Toronto.

The Wellesley Hospital

1995 **Member**, Search Committee, Division of Cardiology, *University of Toronto.*

University of Toronto

1996 **Reviewer**, Human Subjects Review Committee
University of Toronto.

1993 - 1998 **Member**, PGY1 Central Interviewing Team, Department of Medicine, *University of Toronto*.

1993 - 1996 **Member**, Core Curriculum Committee, Postgraduate Medical Education *University of Toronto*.

1993 - 1995 **Member**, Wightman Division Committee on Postgraduate Medical Education, Department of Medicine *University of Toronto*.

1993 - 1994 **Member**, Committee on Continuing Medical Education, Department of Medicine *University of Toronto*.

1992 **Member**, Human Subjects Review Committee *University of Toronto*.

1987 - 1988 **Member**, Committee on Post-Graduate Training in Core Internal Medicine *University*
Residency Training Committee, Faculty of Medicine, University of Toronto., Ontario, Canada.

Wellesley Hospital

1994 - 1998 **Director**, Regional Anaphylaxis Clinic *Wellesley Hospital*.

1996 - 1998 **Member**, Ethics Review Committee *Wellesley Hospital*.

1996 **Member**, Ethics Review Committee, Division of Cardiology *Wellesley Hospital*.

1994 **Member**, Ad Hoc Group, MAC/MSA Executive *Wellesley Hospital*.

1993 - 1996 **Member**, Executive Advisory Committee, Department of Medicine *Wellesley Hospital*.

1993 - 1996 **Member**, CTU Management Committee *Wellesley Hospital*.

1993 - 1996 **Chair**, Interns and Residents Committee, Department of Medicine, *Wellesley Hospital*.

1993 - 1996 **Director**, Postgraduate Medical Education, Department of Medicine, *Wellesley Hospital*.

Wellesley Hospital Research Institute

1992 - 1993 **Member**, Basic Sciences Search Committee *Wellesley Hospital*.

1992 **Chair**, MRC Strategic Planning Group, *Wellesley Hospital*.

1990 - 1995 **Member**, Transition Team, *Wellesley Hospital*.

1990 - 1995 **Member**, Advisory Committee, *Wellesley Hospital*.

OTHER

American Academy of Allergy, Asthma and Immunology

2001 - 2003 **Chair**, Anaphylaxis Committee

1999 - 2001 **Vice Chair**, Anaphylaxis Committee

1996 - present **Member**, Anaphylaxis Committee

Anaphylaxis Canada

2002 - present **Member**, Medical Advisory Board, Anaphylaxis Canada

Anaphylaxis Foundation of Canada

1996 - 2000 **President**

Food Allergy and Anaphylaxis Alliance (Canada)

2002 - present **Member**, Medical Advisory Board

National Peanut Board (U.S.)

2002 - present **Member**, Scientific Advisory Council

Salix Pharmaceuticals, CA

1990 - 1993 **Member**, Scientific Advisory Board.

Peer Review Activities

EDITORIAL BOARDS

Member

1998 - 2006 Canadian Journal of Allergy and Clinical Immunology

1994 - 1998 Journal of Lipid Mediators and Cell Signaling

1994 - 1995 Mediators of Inflammation

North American Editor

1996 - 1999 Mediators of Inflammation

PAST REVIEWER FOR GRANTING AGENCIES

Other

Arthritis Foundation of New Zealand
Atkinson Foundation
Heart and Stroke Foundation of Canada
Medical Research Council of Canada
Ontario Thoracic Society
The Wellcome Foundation, England

PAST REVIEWER FOR JOURNALS / PROCEEDINGS / PANELS

Reviewer

Agents and Actions
American Journal of Obstetrics and Gynecology
American Journal of Respiratory Cell and Molecular Biology
Annals of Allergy Asthma and Immunology
Arteriosclerosis, Thrombosis, and Vascular Biology
Biochimica et Biophysica Acta
Biological Psychiatry
Canadian Journal of Allergy & Clinical Immunology
Circulatory Shock
Clinical Chemistry
European Journal of Hematology
Gut
Inflammation Research
International Archives of Allergy and Clinical Immunology
Journal of Allergy and Clinical Immunology
Journal of Clinical Investigation
Journal of Immunological Methods
Journal of Immunology
Journal of Infectious Diseases
Journal of Lipid Mediators and Cell Signalling

Journal of Rheumatology
Life Sciences
Metabolism
Microvascular Research
Peritoneal Dialysis International
Proceedings of the National Academy of Sciences USA

Other

Elements of Precaution: Recommendations for the Regulation of Food Biotechnology in Canada ((An Expert Panel Report on the Future of Food Biotechnology prepared by The Royal Society of Canada at the request of Health Canada, Canadian Food Inspection Agency and Environment Canada)

Peer Review of the Royal Society of Canada Expert Panel Report (A Review of the Future of Food Biotechnology)

The Canadian Society of Allergy and Clinical Immunology (CSACI), Anaphylaxis in Schools and Other Communities, Consensus Statement 2005

C. Academic Profile

1. RESEARCH STATEMENTS

2011 Jul 1 - 2012 Jun 30

PAF and PAF acetylhydrolase in severe and fatal anaphylaxis: Our study in NEJM 2008 was the first to describe PAF acetylhydrolase deficiency as a risk for fatal anaphylaxis. This has now become recognized as a biomarker for severe anaphylaxis. It is also a designated area of funding for NIH.

Interaction between epinephrine and PAF in PAF-stimulated human vascular smooth muscle cells (Vadas et al J Allergy Clin Immunol 2013): This study is the first to show that epinephrine exerts its therapeutic effect in anaphylaxis by phosphorylation and inactivation of the PAF receptor.

PAF, histamine and tryptase levels in human anaphylaxis (Vadas et al. J Allergy Clin Immunol. 2013): Elevated levels of histamine and tryptase are used to diagnose anaphylaxis but false negative results are frequent. We show that PAF has 100% sensitivity in severe (grade 3) anaphylaxis.

Acquisition of peanut allergy in children of peanut farmers (Submitted for publication): Cutaneous exposure to peanut is thought to predispose to peanut allergy. Households with high levels of environmental peanut exposure are associated with increased risk of acquiring peanut allergy. We conducted a survey of peanut farmers in the southern United States, to estimate the rate of peanut allergy in children growing up on peanut farms with very high levels of environmental peanut exposure. The prevalence of peanut allergy was found to match that in the general population.

Catamenial anaphylaxis in premenopausal women: Perimenstrual (catamenial) anaphylaxis is a rare condition thought to be caused by endogenous anti-progesterone antibody. We describe a series of 8 such patients (Vadas et al. Ann Allergy Asthma Immunol. 2013).

D. Research Funding

1. Grants, Contracts and Clinical Trials

NON-PEER-REVIEWED GRANTS

FUNDED

2008 Jul - 2009 Jun

Co-Principal Investigator. AllerGen (Allergy, Genes and Environment Network). Project

2. Salary Support and Other Funding

Personal Grant Support and Awards

| | |
|-------------|---|
| 2002 | Robyn Allen Award for Individual Achievement. Anaphylaxis Canada. |
| 1991 - 1996 | Career Scholarship. MRC. |
| 1984 - 1986 | Post-Doctoral Fellowship. Medical Research Council. |
| 1980 - 1983 | Medical Scientist Award. Canadian Heart Foundation. |

E. Publications

1. PEER-REVIEWED PUBLICATIONS

Journal Articles

1. Bauer CS., Kampitak T., Messieh ML., Kelly KJ., **Vadas P**. Heterogeneity in presentation and treatment of catamenial anaphylaxis. *Ann Allergy Asthma Immunol* (2013) 1-5. 2013 Jun.
2. **Vadas P**, Perelman B., Liss G. Platelet-activating factor, histamine, and tryptase levels in human anaphylaxis. *J Allergy Clin Immunol*.131(1):144-149. 2013 Jan.
3. **Vadas P**, Perelman B. Effect of epinephrine on platelet-activating factor-stimulated human vascular smooth muscle cell. *J Allergy Clin Immunol*. 129(5):1329-1333. 2012 May.
4. Bauer CS, **Vadas P**, Kelly KJ. Methylene blue for the treatment of refractory anaphylaxis without hypotension. *Am J Emerg Med*. 2013 Jan;31(1):264.e3-5. 2012.
5. Bauer CS, **Vadas P**, Kelly **KJ**. Methylene blue for refractory anaphylaxis-is it a magic bullet? The authors' response. *Am J Emerg Med*. 2013 Jul;31(7):1140-1.
6. Van Wert R, McKenna AM, Smith CA, **Vadas P**, Detsky AS, Mourad O. A missed opportunity. *J Gen Intern Med*. 2013 May;28(5):728-32.
7. Lee JK., **Vadas P**. Anaphylaxis: mechanisms and management.. A comprehensive review of the basic mechanisms and mediators of anaphylaxis and their relevance to treatment. *Clin Exp Allergy* 2011 Jul. 41(7): 923-938
8. Kurian A, Lee JK, **Vadas P**. Schnitzler syndrome with cold-induced urticaria. *J Dermatol Case Rep*. 2010 Dec 31;4(4):50-3.
9. Arias K., Baig M., Colangelo M., Chu D., Walker T., Goncharova S., Coyle A., **Vadas P**, Wasserman S., Jordana M. Concurrent blockade of platelet-activating factor and histamine prevents life-threatening peanut-induced anaphylactic reactions. *J Allergy Clin Immunol* 2009 Aug;124(2):307-14
10. **Vadas P**, Gold M., Perelman B., Liss GM., Lack G., Blyth T., Simons FE., Simons KJ., Cass D., Yeung J. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. *New England Journal of Medicine* 3;358(1):28-35 (2008).
11. Al-Ahmad M, **Vadas P**, Betschel B. Recurrent IgM nephropathy associated with seasonal allergic rhinitis. *European Journal of Allergy and Clinical Immunology*. April 2005.
12. Taylor SL, Hefle SL, Bindslev-Jensen C, Atkins FM, Andre C, Bruijnzeel-Koomen C, Burks AW, Bush RK, Ebisawa

M, Eigenmann PA, Host A, Hourihane JO, Isolauri E, Hill DJ, Knulst A, Lack G, Sampson HA, Moneret-Vautrin DA, Rance F, **Vadas P**, Yunginger JW, Zeiger RS, Salminen JW, Madsen C, Abbott P. A consensus protocol for the determination of the threshold doses for allergenic foods: how much is too much? *Clin Exp Allergy*. 2004 May; 34(5):689-95

13. **Vadas P**, Perelman B. Presence of undeclared peanut protein in chocolate bars imported from Europe. *J Food Protection*. 66(10):1932-4. 2003 Oct. .
14. **Vadas P**, Perelman B. Activated charcoal forms non-IgE binding complexes with peanut proteins. *J Allergy Clin Immunol*. 112(1):175-9. 2003 Jul. .
15. Tsai E, Yeung J, Gold M, Sussman G, Perelman B, **Vadas P**. Study of the allergenicity of plant protein hydrolysates. *Food Allergy and Intolerance*. 4,(2):117-126. 2003.
16. **Vadas P**. Food allergens and anaphylaxis. *Canadian Journal of Dietetic Practice and Research*. 64,(2 insert) 2003.
17. Taylor S, Hefle SL, Bindslev-Jensen C, Bock SA, Burks AW Jr., Christie L, Hill DJ, Host A, Hourihane J O'B, Lack G, Metcalfe DD, Moneret-Vautrin DA, **Vadas P**, Rance F, Skrypec DJ, Trautman TA, Yman IM, Zeiger RS. Factors affecting the determination of threshold doses for allergenic foods: how much is too much? Report of an international conference sponsored by Food Allergy Research & Resource Program. *J Allergy Clin Immunol*. 109:24-30. January 2002.
18. **Vadas P**. Celery Sticks Gone Wrong: An Unexpected Reaction. Case of the Month - The Canadian Journal of Diagnosis. November 2002.
19. **Vadas P**, Wai Y., Burks W., Perelman B. Detection of peanut allergens in breast milk of lactating women. *JAMA* 4:285(13):1746-8. 2001 Apr..
20. **Vadas P**. Systemic cold urticaria. *The Canadian Journal of Diagnosis*. February 2001.
21. **Vadas P**. Allergy to insect venom. *Chronicle of Skin and Allergy*. March 2001.
22. **Vadas P**. Prevention of anaphylaxis in the office setting. *Members Dialogue (CPSO)*. March 2001.
23. Kanani AS, Kalicinsky C, Warrington J, Sussman G, Eisenstat J, Bowen TJ, **Vadas P**. Serum sickness-like reaction with bupropion sustained release. *Cdn J Allergy Clin Imm*, 5:1, 2000.
24. **Vadas P**, Sussman G, Perelman B. Anaphylaxis to cottonseed protein. *Cdn J Allergy Clin Imm* 2000.
25. Koo Seen Lin M, Katz A, Van Den Bosch H, Kennedy B, Stefanski E, **Vadas P**, Pruzanski W. Induction of secretory phospholipase A2 confirms the systemic inflammatory nature of adjuvant arthritis. *Inflammation*, 22(2): 161-173, 1998.
26. Pruzanski W, Stefanski E, **Vadas P**, Kennedy BP, van den Bosch H. Regulation of the cellular expression of secretory and cytosolic phospholipases A2, and cyclooxygenase-2 by peptide growth factors. *Biochim Biophys Acta* 1403:47-56, 1998.
27. **Vadas P**, Gold M. Criteria for development of a priority allergen list: application to sesame seed. *Cdn J Allergy Clin Imm*, 3:4:8-10, 1998.
28. Pruzanski W, Stefanski E, **Vadas P**, McNamara TF, Ramamurthy N, Golub LM. Chemically modified non-antimicrobial tetracyclines inhibit activity of phospholipases A2. *J Rheumatol*, 25:9:1807-12, 1998.
29. Dan P, Dagan A, Krinsky M, Pruzanski W, **Vadas P**, Yedgar S. Inhibition of type I and type II phospholipase A2 by phosphatidyl-ethanolamine linked to polymeric carriers. *Biochemistry* 37:6199-6204, 1998.
30. Pruzanski W, Stefanski E, de Beer FC, de Beer MC, **Vadas P**, Ravandi A, Kuksis A. Lipoproteins are substrates for human secretory group IIA phospholipase A2: preferential hydrolysis of acute phase HDL. *J Lipid Res* 39:2150-2160, 1998.
31. **Vadas P**, Gold M, Graham C. Diagnosis and emergency management of anaphylaxis. *Allergy Sept*. 1998:16 – 22.
32. Dyck ED, **Vadas P**. Anaphylaxis following the application of topical bacitracin. *Eur. J. Allergy Clin. Imm*. 52(8): 870-871, 1997.

33. Pruzanski W, Kennedy BP, van den Bosch H, Stefanski E, **Vadas P**. Microtubule depolymerization selectively down-regulates the synthesis of pro-inflammatory secretory non-pancreatic phospholipase A2. *Lab Invest.* 76(2): 171-178, 1997.
34. **Vadas P**, Grouix B, Stefanski E, Wloch M, Pruzanski W, Schroeder J, Gauldie J. Coordinate expression of group II phospholipase A2 and the acute-phase proteins haptoglobin (HP) and alpha1-anti-chymotrypsin (ACH) by HepG2 cells. *Clin & Exp Immunol.* 108(1):175-180, 1997.
35. Jassal SV, Morton AR, **Vadas P**, Pruzanski W, Stefanski E, Pierratos A. Pro-inflammatory activity of phospholipase A2 in CAPD patients with and without peritonitis. *Periton. Dialysis Internat.* 17:197-199, 1997.
36. **Vadas P**. Group II phospholipases A2 are indirectly cytolytic in the presence of exogenous phospholipid. *Biochim Biophys Acta* 1346(2):193-197, 1997.
37. Pruzanski W, Stefanski E, **Vadas P**, Ramamurthy N. Inhibition of extracellular release of pro-inflammatory secretory phospholipase A2(sPLA2) by sulfasalazine; a novel mechanism of anti-inflammatory activity. *Biochem Pharmacol* 53:1901-1907, 1997.
38. **Vadas P**. Latex-rubber Hypersensitivity. *Allergy* 10(4):31-32, 1997.
39. **Vadas P**. If urticaria/angioedema develops in summer only. *Patient Care* 8(1):18, 1997.
40. **Vadas P**, Stefanski E, Wloch M, Grouix B, van den Bosch H, Kennedy B. Secretory non-pancreatic phospholipase A2 and cyclo-oxygenase-2 expression by tracheo-bronchial smooth muscle cells. *Eur. J. Biochem.* 235:557-563, 1996.
41. Koo Seen Lin M, Farewell V, **Vadas P**, Bookman AAM, Keystone EC, Pruzanski W. Secretory phospholipase A2 as an index of disease activity in rheumatoid arthritis, Prospective double blind study of 212 patients. *J. Rheumatol.* 23(7):1162-1166, 1996.
42. Pruzanski W, Kennedy BP, van den Bosch H, Stefanski E, Wloch M, **Vadas P**. Tenidap sodium inhibits secretory non-pancreatic phospholipase A2 synthesis by fetal rat calvarial osteoblasts. *Mediators of Inflammation* 4:67-70, 1995.
43. Graham C, **Vadas P**. Silicone-gel breast implants and autoimmune connective tissue disease: Is there an association? *Allergy* 8(2):20-24, 1995.
44. Pruzanski W, Urowitz MB, Grouix B, **Vadas P**. Induction of TNF α and pro-inflammatory secretory phospholipase A2 by intravenous administration of CAMPATH - 1H in patients with rheumatoid arthritis. *J. Rheumatol.* 22(10): 1816-1819, 1995.
45. Pruzanski W, de Beer FC, de Beer MC, Stefanski E, **Vadas P**. Serum amyloid A protein enhances the activity of secretory non-pancreatic phospholipase A2. *Biochem. J.* 309:461-464, 1995.
46. Kennedy BP, Payette P, Mudgett J, **Vadas P**, Pruzanski W., Kwan M, Tang C, Rancourt DE, Cromlish WA. A natural disruption of the secretory group II phospholipase A2 gene in inbred mouse strains. *J. Biol. Chem.* 270(38):22378-22385, 1995.
47. Graham C, **Vadas P**. Systemic allergic reactions to corticosteroids. *Practical Allergy and Immunology* 10(5): 182-185, 1995.
48. **Vadas P**, Stefanski E, Grouix B, Schouten BD, Pruzanski W. Inhibition of human group II phospholipase A2 by C-reactive protein in vitro. *J. Lipid Mediators Cell Signalling* 11:187-200, 1995.
49. Pruzanski W, Goulding NJ, Flower RJ, Gladman DG, Urowitz MB, Goodman PJ, Scott KF, **Vadas P**. Circulating group II phospholipase A2 activity and antilipocortin antibodies in systemic lupus erythematosus. Correlative study with disease activity. *J. Rheumatol.* 21(2):252-257, 1994.
50. Pruzanski W, Albin-Cook K, Laxer RM, MacMillan J, Stefanski E, **Vadas P**, Silverman ED. Phospholipase A2 in juvenile rheumatoid arthritis: correlation to disease type and activity. *J. Rheumatol.* 21:1951-1954, 1994.
51. **Vadas P**, Sussman G. Anaphylaxis: Investigation and management at the Regional Anaphylaxis Clinic. *Contemporary Allergies* 4:4-8, 1994.
52. Ellies LG, Heersche JNM, Pruzanski W, **Vadas P**, Aubin JE. The role of phospholipase A2 in interleukin-1 α -mediated inhibition of mineralization of the osteoid formed by fetal rat calvaria cells in vitro. *J. Dental Research*

72(1):18-24, 1993.

53. **Vadas P**, Pruzanski W. Induction of group II phospholipase A2 expression and the pathogenesis of the sepsis syndrome. *Circulatory Shock* 39:160-167, 1993.
54. Koo Seen Lin MJ, Keystone EC, **Vadas P**, Pruzanski W. Cytokines in rheumatoid arthritis: Implications for therapeutic immunotargeting. *Practical Immunology and Allergy* 8(2):65-69, 1993.
55. **Vadas P**, Sussman G. Allergy to peanuts and related foods. *Contemporary Allergies* 3:10-18, 1993.
56. **Vadas P**, Reid B, Roifman C, Pruzanski W. Serum phospholipase A2 activity in congenital immunodeficiency syndromes during infections and infection-free intervals. *Life Sciences Advances* 12(1):9-16, 1993.
57. **Vadas P**, Taylor TE, Chimsuku L, Goldring D, Stefanski E, Pruzanski W, Molyneux ME. Increased serum phospholipase A2 activity in Malawian children with falciparum malaria. *Am. J. Trop. Med. Hygiene.* 49(4): 455-459, 1993.
58. **Vadas P**, Schouten B, Stefanski E, Scott K, Pruzanski W. Association of hyperphospholipasemia A2 with multiple system organ dysfunction due to salicylate intoxication. *Crit. Care Med.* 21(7):1087-1091, 1993.
59. **Vadas P**, Browning J, Edelson J, Pruzanski W. Extracellular phospholipase A2 expression and inflammation: the relationship with associated disease states. *J. Lipid Mediators* 8:1-30, 1993.
60. Pruzanski W, **Vadas P**, Browning J. Secretory non-pancreatic group II phospholipase A2: role in physiologic and inflammatory processes. *J. Lipid Mediators* 8:161-167, 1993.
61. **Vadas P**. Allergic rhinitis: always in season. *Contemporary Allergies* 4(1): 4-8. 1993.
62. Lee A, **Vadas P**. Multiple drug allergies in patients with acquired immune deficiency syndrome (AIDS). *Contemporary Allergies* 4(1): 12-15, 1993.
63. Pruzanski W, Sherman MI, Kufe DW, **Vadas P**. Hyperphospholipasemia A2 following intravenous infusion of tumor necrosis factor in man. *Mediators of Inflammation.* 1:235-240, 1992.
64. Pruzanski W, Wilmore DW, Suffredini AF, Martich GD, Hoffman AGD, Browning JL, Stefanski E, Sternby B, **Vadas P**. Hyperphospholipasemia A2 in human volunteers challenged with intravenous endotoxin. *Inflammation* 16(5): 561-570, 1992.
65. **Vadas P**, Keystone J, Stefanski E, Scott K, Pruzanski W. Induction of circulating group II phospholipase A2 in adults with malaria. *Infection Immunity* 60(9):3928-3931, 1992.
66. **Vadas P**, Scott K, Smith G, Rajkovic I, Stefanski E, Schouten B, Singh R, Pruzanski W. Serum phospholipase A2 enzyme activity and immunoreactivity in a prospective analysis of patients with septic shock. *Life Sciences* 50:807-811, 1992.
67. Pruzanski W, Greenwald R, Street IT, Laliberte F, Stefanski E, **Vadas P**. Inhibition of enzymatic activity of phospholipases A2 by minocycline and doxycycline. *Biochem. Pharmacol.* 44(6):1165-1170, 1992.
68. **Vadas P**, Sussman G. An approach to the patient with suspected immunodeficiency. *Contemporary Allergies* 2:4-8, 1992.
69. Pruzanski W, Scott K, Smith G, Rajkovic I, Stefanski E, **Vadas P**. Enzymatic activity and immunoreactivity of extracellular phospholipase A2 in inflammatory synovial fluids. *Inflammation* 16(5):451-459, 1992.
70. **Vadas P**, Leznoff A, Sussman G. Examining the immunologic reaction to breast implants. *Canadian J Diagnosis* 9:53-61, 1992.
71. Pruzanski W, **Vadas P**. Should tetracycline be used in arthritis? *J. Rheumatol.* 19:1495-1497, 1992.
72. Pruzanski W, Mackensen A, Engelhardt R, Stefanski E, **Vadas P**. Induction of circulating phospholipase A2 activity by intravenous infusion of endotoxin in patients with neoplasia. *J. Immunotherapy* 12:242-246, 1992.
73. Pruzanski W, **Vadas P**. Phospholipase A2 - a mediator between proximal and distal effectors of inflammation. *Immunology Today.* 12(5):143-146, 1991.
74. Pruzanski W, Saito S, Stefanski E, **Vadas P**. Comparison of group I and II soluble phospholipases A2 activities on phagocytic functions of human polymorphonuclear and mononuclear phagocytes. *Inflammation* 15(2):127-135,

1991.

75. **Vadas P**, Pruzanski W, Stefanski E, Ellies LG, Aubin JE, Sos A, Melcher A. Extracellular phospholipase A2 secretion is a common effector pathway of interleukin-1 and tumour necrosis factor action. *Immunology Letters* 28:187-194, 1991.
76. Pruzanski W, Bogoch E, Wloch M, **Vadas P**. The role of phospholipase A2 in physiopathology of osteoarthritis. *J. Rheumatol* 18 (Suppl.27): 117-119, 1991.
77. **Vadas P**, Pruzanski W, Farewell V. A predictive model for the clearance of soluble phospholipase A2 during septic shock. *J. Lab. Clin. Med.* 118(5):471-475, 1991.
78. Ellies LG, Heersche JNM, **Vadas P**, Pruzanski W, Stefanski E, Auben JE. Interleukin-1a stimulates the release of prostaglandin E2 and phospholipase A2 from fetal rat calvarial cells in vitro: relationship to bone nodule formation. *J. Bone Mineral Res.* 6(8):843-850, 1991.
79. Edelson J, **Vadas P**, Villar J, Mullen J, Pruzanski W. Acute lung injury induced by phospholipase A2: Structural and functional changes. *Amer. Rev. Resp. Dis.* 143: 1102-1109, 1991.
80. **Vadas P**, Pruzanski W. Plasma cortisol levels in patients with septic shock. *Critical Care Med.* 19(2): 300-301, 1991. (PI) (Letter).
81. **Vadas P**, Pruzanski W. Cortisol response to corticotropin and survival in septic shock. *Lancet* 337:1230-1231, 1991. (Letter).
82. Pruzanski W, Bogoch E, Stefanski E, Wloch M, **Vadas P**. Enzymatic activity and distribution of phospholipase A2 in human cartilage. *Life Sciences* 48:2457-2462, 1991.
83. **Vadas P**, Pruzanski W. Serum phospholipase A2 values and septic shock. *Crit. Care Med.* 19(7): 988-989, 1991. (Letter).
84. **Vadas P**, Sussman G. Idiopathic anaphylactic reactions: diagnosis and management. *Practical Allergy Immunol.* 6(3):95-98, 1991.
85. Pruzanski W, Bogoch E, **Vadas P**. Phospholipase A2 in articular cartilage. *J Rheumatol.* 17:569-572, 1991.
86. Pruzanski W, **Vadas P**. Phospholipase A2 and inflammation. *Ann Rheum. Dis.* 48:962-963, 1990. (Letter).
87. **Vadas P**, Pruzanski W, Stefanski E, Sternby B. Compartmental heterogeneity of soluble phospholipases A. *Inflammation* 14(2):173-183, 1990.
88. Pruzanski W, **Vadas P**. Phospholipase A2 in articular cartilage. *J. Rheumatol.* 17:569-570, 1990. (Letter).
89. Pruzanski W, Lee P, Stefanski E, Sternby B, **Vadas P**. Hypophospholipasemia A2 in systemic sclerosis. *J. Rheumatol.* 17(9):1182-1186, 1990.
90. Pruzanski W, **Vadas P**. Interleukin-6 and phospholipase A2 in sepsis. *Blood* 75: 1897-1898, 1990. (Letter).
91. Pruzanski W, Bogoch E, Stefanski E, Wloch M, **Vadas P**. Synthesis and release of phospholipase A2 by unstimulated human articular chondrocytes. *J. Rheumatol.* 17(10):1386-1391, 1990.
92. Seilhamer JJ, Pruzanski W, **Vadas P**, Plant S, Miller JA, Kloss J, Johnson LK. Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid. *J. Biol. Chem.* 264(10):5335-5338, 1989.
93. Seilhamer JJ, Plant S, Pruzanski W, Schilling J, Stefanski E, **Vadas P**, Johnson LK. Multiple forms of phospholipase A2 in arthritic synovial fluid. *J. Biochem.* 106:38-42, 1989.
94. **Vadas P**, Pruzanski W, Kim J, Fornasier V. The pro-inflammatory effect of intra-articular injection of soluble human and venom phospholipase A2. *Am. J. Pathol.* 134(4):807-811, 1989.
95. **Vadas P**, Pruzanski W, Stefanski E, Sternby B, Mustard R, Bohnen J, Fraser I, Farewell V, Bombardier C. The pathogenesis of hypotension in septic shock: Correlation of circulating phospholipase A2 levels with circulatory collapse. *Crit. Care Med.* 16:1-7, 1988.
96. **Vadas P**, Pruzanski W, Stefanski E. Extracellular phospholipase A2: causative agent in circulatory collapse of

septic shock? Agents and Actions 24:320-325, 1988.

97. **Vadas P**, Pruzanski W, Stefanski E, Ruse J, Farewell V, McLaughlin J, Bombardier C. Concordance of endogenous cortisol and phospholipase A2 levels in gram-negative septic shock: a prospective study. *J. Lab. Clin. Med.* 111(5):584-590, 1988.
98. Pruzanski W, **Vadas P**, Kim J, Jacobs H, Stefanski E. Phospholipase A2 activity associated with synovial fluid cells. *J. Rheumatol.* 15(5):791-794, 1988.
99. Pruzanski W, Stefanski E, **Vadas P**. Secretory synovial fluid phospholipase A2 and its role in the pathogenesis of inflammation in arthritis. *J. Rheumatol.* 15(11):1601-1603, 1988.
100. Pruzanski W, Keystone E, Bombardier C, Snow K, Sternby B, **Vadas P**. Serum phospholipase A2 correlates with disease activity in rheumatoid arthritis. *J. Rheumatol.* 15(9):1351-1355, 1988.
101. **Vadas P**, Stefanski E, Pruzanski W. Influence of plasma proteins on activity of pro-inflammatory enzyme phospholipase A2. *Inflammation* 10(2):183-193, 1986.
102. Pruzanski W, **Vadas P**, Fornasier V. Inflammatory effect of intra-dermal administration of soluble phospholipase A2 in rabbits. *J. Invest. Dermatol.* 86(4):380-383, 1986.
103. **Vadas P**, Pruzanski W. Role of secretory phospholipase A2 in the pathobiology of disease. *Lab. Invest.* 55(4):391-404, 1986.
104. **Vadas P**, Stefanski E, Pruzanski W. Potential therapeutic efficacy of inhibitors of human phospholipase A2 in septic shock. *Agents and Actions* 19:194-202, 1986.
105. Stefanski E, Pruzanski W, Sternby B, **Vadas P**. Purification of soluble phospholipase A2 from synovial fluid in rheumatoid arthritis. *J. Biochem.* 100(5):1297-1303, 1986.
106. Pruzanski W, **Vadas P**. Experimental evidence for a proinflammatory effect of phospholipase A2 on joint tissues. *J. Rheumatol* 13(5):990-991, 1986.
107. Pruzanski W, **Vadas P**, Stefanski E, Urowitz MB. Phospholipase A2 activity in sera and synovial fluids in rheumatoid arthritis and osteoarthritis, Its possible role as a pro-inflammatory enzyme. *J. Rheumatol.* 12(2): 211-216, 1985.
108. **Vadas P**, Stefanski E, Pruzanski W. Characterization of extracellular phospholipase A2 in rheumatoid synovial fluid. *Life Sci.* 36:579-587, 1985.
109. **Vadas P**, Pruzanski W. Role of extracellular phospholipase A2 in inflammation. *Advances in Inflammation Research.* 7:51-62, 1984.
110. **Vadas P**. Involvement of circulating phospholipase A2 in the pathogenesis of the hemodynamic and pulmonary changes in gram-negative septic shock. *J. Lab. Clin. Med.* 104:973-981, 1984.
111. Gordon M, **Vadas P**. Benefits of access to on-site acute and critical care for the residential section of a multi-level geriatric centre. *J. Amer. Geriatric. Soc.* 32(6):453-456, 1984.
112. **Vadas P**, Hay JB. Involvement of circulating phospholipase A2 in the pathogenesis of the hemodynamic changes in endotoxin shock. *Can. J. Physiol. Pharmacol.* 61(6):561-566, 1983.
113. **Vadas P**. The efficacy of anti-inflammatory agents with respect to extracellular phospholipase A2 activity. *Life Sciences* 30(2):155-162, 1982.
114. **Vadas P**, Hay JB. The appearance and significance of phospholipase A2 in lymph draining tuberculin reactions. *Am. J. Pathol.* 107(3):285-291, 1982.
115. Wasi S, **Vadas P**, Chin GW, Movat HZ, Hay JB. The production of plasminogen activator by afferent but not efferent lymph cells emigrating from chronic granulomatous lesions in sheep. *J. Immunol.* 128:1076-1082, 1982.
116. **Vadas P**, Wasi S, Movat HZ, Hay JB. Extracellular phospholipase A2 mediates inflammatory hyperemia. *Nature* 292: 583-585, 1981.
117. Hamilton J, **Vadas P**, Hay JB. Measurement of blood flow and vascular permeability changes in response

to 12-0-tetradecanoyl-phorbol-13-acetate and to asbestos fibres. *J. Toxicol. Environ. Health.* 8:205-214, 1981.

118. Hay JB, Johnston MG, **Vadas P**, Chin W, Issekutz T, Movat HZ. Relationships between changes in blood flow and lymphocyte migration induced by antigen. *Monographs in Allergy Series*, 16:112-125, 1980.
119. **Vadas P**, Hay JB. Secretion of a hyperemia-inducing moiety by mitogen or glycogen stimulated mononuclear inflammatory cells of sheep and rabbit. *Int. Arch. Allergy. Appl. Immunol.* 62:142-151, 1980.
120. **Vadas P**, Hay JB. The release of phospholipase A2 from aggregated platelets and stimulated macrophages of sheep. *Life Sciences* 26:1721-1729, 1980.
121. **Vadas P**, Wasi S, Movat HZ, Hay JB. A novel, vasoactive product and plasminogen activator from afferent lymph cells draining chronic inflammatory lesions. *Proc. Soc. Exp. Biol. Med.* 161:82-85, 1979.
122. **Vadas P**, Hay JB. Cutaneous blood flow measurements: A standardization of the microsphere assay for vasoactive agents. *Agents and Actions.* 8(5):504-508, 1978.

Case Reports

1. Lee JK and **Vadas P**. An elusive case of mastocytosis. *Allergy, Asthma and Clinical Immunology.* 6 (supplement 1):24. 2010. **Coauthor or Collaborator.**
2. Mace SR, **Vadas P**, Pruzanski W. Anaphylactic shock induced by intra-articular injection of methylprednisolone acetate: a case report and review of the literature. *J. Rheumatol.* 24:1191-1194, 1997.

Book Chapters

1. Al-Ahmad M, Betschel SD, Guest Editor: **Vadas P**. The Anaphylactic Patient. *Respirology & Allergy Rounds.* Volume 3, Issue 4. May-June 2006.
2. **Vadas P**, Edelson J, Pruzanski W. Phospholipase A2 and the pathogenesis of multisystem organ failure in experimental and clinical endotoxin shock. In "Esterases, Lipases and Phospholipases: From Structure to Clinical Significance." eds: M.I. Mackness, and M. Clerc. NATO ASI Series - Proceedings 1993 Series A: Life Sciences 266:203-211, 1994. Plenum Press, New York and London.
3. Pruzanski W, deBeer FC, Kennedy B, Stefanski E, **Vadas P**. Modulation of pro-inflammatory phospholipase A2 by acute phase reactants and microtubular disrupters. In "Lipid Mediators in Health and Disease" (LMHD). Ed. U. Zor. pp. 33-38. Freund Publishing House Ltd., London, Tel Aviv. 1994.
4. **Vadas P**, Pruzanski W. Signal transduction: Phospholipase A2, Fatty Acids & Inflammation. in: *Omega-3 Fatty Acids Metabolism & Biological Effects* eds. C.A. Drevon, I. Baksaas, H. Krokan. pp.87-96. Birkhäuser Verlag A.G., Basel, 1993.
5. **Vadas P**, Pruzanski W. Phospholipase A2 activation is the pivotal step in the effector pathway of inflammation. in: *Phospholipase A: Role and function in inflammation.* Eds. Dennis, E and Wong P.Y.K. Plenum Press 275:83-101, 1990.
6. Pruzanski W, **Vadas P**. Soluble phospholipase A2 in human pathology. Clinical laboratory interface. In: *Biochemistry, molecular biology and physiology of phospholipase A2 and its regulatory factors.* Ed. Anil B. Mukherjee, Plenum Press 1990.
7. Johnson LK, Frank S, **Vadas P**, Pruzanski W, Marian-Scardina J, Lusi AJ, Seilhamer JJ. Localization and evolution of human phospholipase A2 genes and two related genetic elements. in: *Phospholipase A2: role and function in inflammation.* Eds. Dennis E., and Wong P.Y.K. Plenum press, New York 1990.
8. Seilhamer J, **Vadas P**, Pruzanski W, Plant S, Stefanski E, Johnson L. Synovial fluid phospholipase A2 in arthritis. in: *Therapeutic approaches in inflammatory diseases.* Lewis A.J., Doherty N.S., Ackerman N.R. eds. Elsevier, NY 1989.
9. **Vadas P**, Pruzanski W, Stefanski E, Johnson L, Seilhamer J, Mustard R Jr, Bohnen J. Phospholipase A2 in acute bacterial peritonitis in man. in: *Cell Activation and Signal Initiation: Receptor and phospholipase control of inositol phosphate, PAF, and eicosanoid production.* pp.311-316. Eds. Dennis E.A., Hunter T, and Berridge M. Alan R. Liss, N.Y. 1989.
10. **Vadas P**, Pruzanski W. The role of extracellular phospholipase A2 in inflammation. In: *Advances in inflammation*

research Eds. Capetolla, R and Otterness, Vol.7: 5162, 1983 Raven Press, N.Y.

11. Lee J, **Vadas P**. Management Protocols for Severe Anaphylaxis in Cuidados Protocolos (Intensive Care Protocols) ed Sancho Rogriguez Villar Marban.2012. 2012. **Coauthor or Collaborator**.
12. **Vadas P**, Pruzanski W. Inter-relationship of phospholipase A2 and lipid peroxidation in multisystem organ failure in septic shock. Progress in Surgery. Phospholipase A2: Basic and Clinical Aspects in Inflammatory Diseases. eds. W.Uhl, T.J.Nevalainen and M.W.Büchler. Karger Press, Basel, 1997.
13. Pruzanski W, **Vadas P**. Secretory non-pancreatic phospholipase A2 (sPLA2) as a mediator of inflammation. Birkhäuser Verlag A.G., Basel, 1996.
14. Kennedy BP, **Vadas P**, Pruzanski W. Secretory PLA2-deficient and transgenic mice in phospholipase A2 Research. Progress in Surgery. Phospholipase A2: Basic and Clinical Aspects in Inflammatory Diseases. eds. M.Buchler and W.Uhl. Karger Press, Basel, 1996.
15. Scott K, **Vadas P**. Non-pancreatic (Type II) Phospholipase A2 in septic shock. In “Phospholipase A2 in clinical inflammation: endogenous regulation and pathophysiological actions.” eds. K Glaser and P. Vadas. CRC Press, Boca Raton, Florida, USA. 1995. In Press.
16. **Vadas P**, Glaser K. Biology of phospholipase A2 in systemic inflammatory response syndrome. In “Biology of Phospholipase A2: Pharmacology and Associated Diseases” Eds. K. Glaser and P. Vadas. Birkhäuser Verlag A.G., Basel 1995.
17. Pruzanski W, Koo Seen Lin M, **Vadas P**. Secretory phospholipase A2 in rheumatic diseases. In “Phospholipase A2 in clinical inflammation: molecular approaches to pathophysiology.” eds. K Glaser and P. Vadas. CRC Press, Boca Raton, Florida, 1995.

Editorials

1. **Vadas, P**. Guest Editorial. Cdn J Allergy Clin Imm, 4(3):110, 1999.
2. **Vadas P**. Editorial. Allergy (1996).

Letters to Editor

1. **Vadas, P**. Letter to the Editor. Cdn J Allergy Clin Imm, Nov. 1998, page 303.

Monographs

1. **Vadas P** et al. Anaphylaxis in schools and other settings. Published in conjunction with the Canadian Society of Allergy and Clinical Immunology and Anaphylaxis Canada. 2010. **Coauthor or Collaborator**

2. NON-PEER-REVIEWED PUBLICATIONS

Journal Articles

1. **Vadas P**. Allergy to Casein: Are people allergic or sensitive to casein? How do you diagnose it if you are? The Canadian Journal of CME. Consultant's Corner. February 2009. **Principal Author**.
2. **Vadas P**. Food Allergy Testing in Children with Mild Urticaria: In children with mild urticaria, would they benefit from food allergy testing? The Canadian Journal of CME. Consultant's Corner. March 2009. **Principal Author**.
3. **Vadas P**. Acrylate Allergy: Is it common that workers (or clients) have an allergy (respiratory or skin) to gel nail products which contain acrylate? The Canadian Journal of CME. March 2009. **Principal Author**.
4. **Vadas P**. Antihistamines: Why do oral antihistamines not have any affect on allergic conjunctivitis? Most allergic patients require antihistamine eye drops in addition to antihistamines? The Canadian Journal of CME. Consultant's

Corner. April 2009. **Principal Author.**

5. **Vadas P.** Oral Allergy Syndrome: Oral allergy syndrome is a clinical diagnosis in general and skin testing is generally not helpful or indicated. It seldom leads to full-blown anaphylactic reaction. Is there any recent thought or study to suggest otherwise? The Canadian Journal of CME. Consultant's Corner. April 2009. **Principal Author.**
6. **Vadas P.** Peanut Allergy: Do children outgrow peanut allergy and is there a way to test for this? The Canadian Journal of CME. Consultant's Corner. April 2009. **Principal Author.**
7. **Vadas P.** ACE Inhibitors for Patients with Past Anaphylaxis: Should ACE inhibitors not be used in patients with past history of anaphylaxis? The Canadian Journal of CME. Consultant's Corner. May 2009. **Principal Author.**
8. **Vadas P.** Symptoms Triggered from Monosodium Glutamate: How does Monosodium glutamate (MSG) act in Chinese food? Some have no symptoms and some people get very sick. The Canadian Journal of CME. Consultant's Corner. May 2009. **Principal Author.**
9. **Vadas P.** The Radioallergosorbent Test: Where does radioallergosorbent test [RAST] fit into the allergy work-up? What are its limitations? The Canadian Journal of CME. Consultant's Corner. November/December 2008. **Principal Author.**
10. **Vadas P.** Omega-3 Supplements and Allergies: Can patients allergic to fish and seafood take omega-3 supplements? Is there a risk of allergy? The Canadian Journal of CME. Consultant's Corner. July 2008. **Principal Author.**
11. **Vadas P.** When to Introduce Highly Allergenic Foods: Which foods should be avoided in young children due to allergy concerns (e.g., strawberries, peanut butter)? Why? And when can they be introduced? The Canadian Journal of CME. Consultant's Corner. August 2008. **Principal Author.**
12. **Vadas P.** Egg Allergy and the Influenza Vaccine: If a patient received influenza vaccine in the past, but tests positive for egg yolk allergy, do you still give the vaccine? The Canadian Journal of CME. Consultant's Corner. October 2008. **Principal Author.**
13. **Vadas P.** Do all shellfish allergy patients require an epinephrine injection? The Canadian Journal of CME. Consultant's Corner. April 2008. **Principal Author.**
14. **Vadas P.** How common are sulphite allergies and do you test for them? The Canadian Journal of CME. Consultant's Corner. May 2008. **Principal Author.**
15. **Vadas P.** Allergy Testing: Should we refer patients for allergy testing if they are known to have many environmental allergies and who do not wish to have desensitizing injections? The Canadian Journal of CME. Consultant's Corner. November/December 2008. **Principal Author.**
16. **Vadas P.** Immunology tolerance to felines. (Consultant's Corner). The Canadian Journal of CME. November 2007.
17. **Vadas P.** Is an ongoing cough an allergy? (Consultant's Corner). The Canadian Journal of CME. November 2007.
18. **Vadas P.** Remind anaphylactic patients about proper management, up-to-date meds. The Medical Post. 2007 January 23.
19. **Vadas P.** Is there a relationship between food and eczema? (Consultant's Corner). The Canadian Journal of CME. February 2007.
20. **Vadas P.** Fish allergy. (Consultant's Corner). The Canadian Journal of CME. February 2007.
21. **Vadas P.** Desensitizing allergies. What is the evidence for allergy desensitization? (Consultant's Corner). The Canadian Journal of CME. January 2006.
22. **Vadas P.** Be forewarned about fruit. What are the most allergic fruit and why? (Consultant's Corner). The Canadian Journal of CME. February 2006.
23. **Vadas P.** Be Aware, Be Prepared. Key Management Strategies. Clinical Focus on Anaphylaxis. Medical Post Supplement. February 2006.
24. **Vadas P.** Banana allergy. A mother describes her child as having an allergy to banana (tongue and lip swelling). Given cross-reactivity, should the child be tested for latex allergy? (Consultant's Corner). The Canadian Journal of CME. March 2006.
25. **Vadas P.** Kiwi allergy. "I have a young, otherwise healthy male patient, who reports being allergic to kiwi (tongue

swelling). Is it necessary to be tested against latex and shellfish given the cross-sensitivity to these particular antigens? (Consultant's Corner). The Canadian Journal of CME. April 2006.

26. **Vadas P.** Pregnancy and peanut avoidance. Is there evidence for peanut avoidance during pregnancy? If so, what is the risk of severe allergies developing in childhood? (Consultant's Corner). The Canadian Journal of CME. April 2006.
27. **Vadas P.** Parental anaphylaxis. Is Hx of parental anaphylaxis to medication (e.g. penicillin) significant? What about other first-degree relatives? (Consultant's Corner). The Canadian Journal of CME. April 2006.
28. **Vadas P.** First aid for food allergies. What drug do you suggest a GP carry to restaurants as first aid for people with food allergies, since Benadryl has been discounted? (Consultant's Corner). The Canadian Journal of Diagnosis. May 2006.
29. **Vadas P.** Prevention of chronic sinusitis. Please discuss long-term prevention of chronic allergic sinusitis. (Consultant's Corner). The Canadian Journal of CME. May 2006.
30. **Vadas P.** Immunizing children with egg allergies: What are the pros and cons of immunizing children with egg allergies for the flu? (Consultant's Corner). The Canadian Journal of CME. June 2006.
31. **Vadas P.** The avoidance of certain foods in children: Should any foods be avoided until a certain age in children (e.g., peanuts, strawberries, eggs) and what is the reasoning for this? (Consultant's Corner). The Canadian Journal of CME. June 2006.
32. **Vadas P.** Breast milk allergy: Is there a true allergy or incompatibility for infants to breast milk? (Consultant's Corner). The Canadian Journal of CME. July 2006.
33. **Vadas P.** Is skin testing useful for skin allergies? How reliable is skin testing for determining skin allergies? (Consultant's Corner). The Canadian Journal of CME. July 2006.
34. **Vadas P.** Does an allergic reaction causing hives warrant an EpiPen? (Consultant's Corner). The Canadian Journal of CME. August 2006.
35. Dube N, Schellenberg R, **Vadas P.** Asthma: A heterogeneous syndrome. Emerging Therapies in Asthma & Allergy. Vol. 1/No. 3. Tamarind Healthcare Communications Inc. 2006.
36. Alsowaidi S, **Vadas P.** Peanut allergy: An overview. Allergy & Asthma. A Canadian Review for Primary Care Physicians. Summer 2006.
37. **Vadas P.** The relationship between food and eczema. (Consultant's Corner). The Canadian Journal of CME. September 2006.
38. **Vadas P.** The reliability of skin testing. (Consultant's Corner). The Canadian Journal of CME. October 2006.
39. **Vadas P.** How serious is hay fever? (Consultant's Corner). The Canadian Journal of CME. November 2006.
40. **Vadas P.** When to consider allergy shots. (Consultant's Corner). The Canadian Journal of CME. December 2006.
41. **Vadas P.** Does early vitamin use lead to food allergies? (Consultant's Corner). The Canadian Journal of CME. June 2005.
42. **Vadas P.** Epinephrine and allergies. Other than peanut and penicillin allergies, which other allergies justify an epinephrine prescription? (Consultant's Corner). The Canadian Journal of CME. October 2005.
43. **Vadas P.** Outgrowing allergies. When does a child outgrow egg allergies? (Consultant's Corner). The Canadian Journal of CME. December 2005.
44. **Vadas P.** The truth behind allergies. The Canadian Journal of CME. 110-116, January 2004.
45. **Vadas P.** Overview of Common Issues in the Management of Allergic Disease. Patient Care Canada. Vol. 15, No. 3:60-63. March 2004.
46. **Vadas P.** Allergies to OTC vitamins (Experts on Call). The Canadian Journal of Diagnosis. April 2004.
47. **Vadas P.** What winter-month allergen returns negative on testing? (You asked about ...). The Canadian Journal of Diagnosis. June 2004.

48. **Vadas P.** Thimerosal Allergy: Is it a concern? *The Canadian Journal of Diagnosis*. August 2004.
49. **Vadas P.** National Advisory Committee on Immunization (NACI). Statement on thimerosal. [Article in English, French] *Can Commun Dis Rep*. 2003 Mar 1;29:1-10. **Contributor**.
50. **Vadas P.** On the Table: Food Allergies. *The Canadian Journal of Diagnosis*. August 2003.
51. **Vadas P.** Latex-Rubber Hypersensitivity. *Allergy*, 10(4):31-32, 1997.
52. **Vadas P.** If urticaria/angioedema develops in summer only. *Patient Care* 8(1):18 (1997). Letter.
53. **Vadas P**, Pruzanski W. The role of secretory phospholipase A2 in the pathobiology of disease. *Lab. Invest.* 55:391-404, 1986. **Principal Author**.

Abstracts

1. **Vadas P.** Anaphylaxis: pathways, mediators and modulation. *American Academy of Allergy, Asthma and Immunology*. March 2007.
2. **Vadas P.** Xolair in the treatment of moderate to severe asthma. *Humber River Hospital*. October 2006.
3. **Vadas P.** Allergic Rhinitis. *The Journal Club of Chinatown Physicians*. Blue Mountain Winter Symposium. February 2003 (Sponsor: Schering Canada).
4. **Vadas P.** PAF-AH predisposes to fatal anaphylaxis. *National Peanut Board, Scientific Advisory Council Meeting*. Atlanta. January 2002.
5. **Vadas P.** Future therapies for peanut and nut allergies. *Peanut Bureau of Canada Launch Event*. Toronto. February 2002.
6. **Vadas P.** Chronic urticaria: a practical approach to a difficult problem. *Schering Canada Workshop*. Collingwood. February 2002.
7. **Vadas P.** Breast Feeding and Food Allergy. *AAAAI Annual Meeting*. New York. March 2002.
8. Salter J, Mehra S, Cohen D, Gold M, **Vadas P.** A retrospective review of food allergy-related 911 calls in the Greater Toronto area. *CSACI Annual Meeting*. Quebec City. November 2002.
9. **Vadas P**, Gold M. Perplexing case histories. *Allergy, Asthma and Immunology Society of Ontario*. January 2001.
10. **Vadas P.** Activated charcoal forms complexes with peanut protein preventing IgE binding. *Allergy Research Forum, The Peanut Foundation*. Fairfax, Virginia. August 2001.
11. **Vadas P.** Food Allergy. *Allergy Clinic Day 2001*. Kitchener. October 2001.
12. **Vadas P.** What is the future of food allergy? Prevention and therapy? *CSACI Annual Scientific Meeting*. Banff, Alberta. October 2001.
13. **Vadas P.** Threshold Effects: Animal Models to detect allergenicity to foods and genetically modified products. *Health Canada Workshop*. Ottawa. November 2001.
14. **Vadas P.** Anaphylaxis: Prevention and Management. *Allergy Update 2000, AAISO*. Toronto 2000.
15. **Vadas P**, Gold M, Evans M. Managing Anaphylaxis: Q&A. *The Medical Post* 2000.
16. **Vadas P.** You can't judge a chocolate bar by its cover: get the facts behind the label. *Anaphylaxis Network Newsletter*. December 2000.
17. **Vadas P.** Occult sensitization of anaphylactically sensitive children. *Hospital for Sick Children, Division of Immunology*. Toronto. 1999.
18. **Vadas P**, Sussman G, Perelman B. Allergenicity of cottonseed oil. *First International Symposium on Anaphylaxis*. Toronto. 1999.
19. Esmail N, Perelman B, **Vadas P.** Pyrethrum-induced anaphylaxis in a case of attempted homicide. *First International Symposium on Anaphylaxis*. Toronto. 1999.

20. **Vadas P**, Wai Y, Hizaka M, Perelman B, Burks W. Detection of peanut allergens in breast milk of lactating women. First International Symposium on Anaphylaxis. Toronto. 1999.
21. Weinreich D, Cass D, **Vadas P**. Emergency room management of acute anaphylaxis. First International Symposium on Anaphylaxis. 1999.
22. Tsai E, Yeung J, Gold M, Sussman G, Perelman B, **Vadas P**. Study of the Allergenicity of Plant Protein Hydrolysates. AAAAI Annual Meeting, Orlando, Fla. 1999.
23. **Vadas P**. Maternal dietary peanut protein secreted in breast milk during lactation. The Peanut Foundation Annual General Meeting, Washington, DC. 1999.
24. **Vadas P**. Trace exposures causing anaphylactic deaths. Thresholds for Allergenic Foods: How much is too much? Hilton Head Island, South Carolina. 1999.
25. Yip LH, Stefanski E, Pruzanski W, **Vadas P**. Secretory phospholipase A2 levels in acute exacerbations of asthma. AAAAI Annual Meeting, Washington, DC. 1998.
26. **Vadas P**, Pruzanski W. Secretory Phospholipase A2 expression and the pathogenesis of septic shock. Third International Congress of WHMA, Pecs, Hungary 1996.
27. **Vadas P**. Phospholipase A2 - induced cellular dysfunction is a two-hit event. Institut Pasteur, Paris, France. 1996.
28. **Vadas P**. Secretory Phospholipase A2 in septic shock and multisystem organ failure. Erasmus University, Rotterdam, The Netherlands. 1996.
29. Pruzanski W, Stefanski E, **Vadas P**. Sulfasalazine inhibits expression of proinflammatory secretory phospholipase A2. 10th International Congress on Prostaglandins and Related Compounds. Vienna, Austria. 1996.
30. Pruzanski W, Kennedy BP, van den Bosch H, Stefanski E, **Vadas P**. Microtubule depolymerization selectively downregulates the synthesis of proinflammatory secretory phospholipase A2. 10th International Congress on Prostaglandins and Related Compounds. Vienna, Austria. 1996.
31. Pruzanski W, **Vadas P**, de Beer FC. Impact of secretory phospholipase A2 on high density lipoprotein. A new mechanism of inflammatory aspect of atherosclerosis? 10th International Congress on Prostaglandins and Related Compounds. Vienna, Austria. 1996.
32. Kennedy BP, Payette P, Cromlish WA, **Vadas P**, Pruzanski W, Gallinger S, Bapat B. Disruption of the secretory PLA2 gene in inbred mouse strains and possible links to colon cancer. 10th International Congress on Prostaglandins and Related Compounds. Vienna, Austria. 1996.
33. **Vadas P**, Grouix B, Stefanski E, Koo Seen Lin M, Pruzanski W. The effect of lipid peroxidation on human secretory phospholipase A2 (sPLA2)-mediated degradation of cell membranes. 5th Vienna Shock Forum. Vienna, Austria 1995.
34. Pruzanski W, Stefanski E, **Vadas P**. Endogenous modulation of proinflammatory secretory phospholipase A2 (sPLA2) activity. 5th Vienna Shock Forum. Vienna, Austria. 1995.
35. **Vadas P**, Casey L, Pruzanski W. Anti-LPS antibody therapy in septic shock: The effect on secretory phospholipase A2 activity. 5th Vienna Shock Forum. Vienna, Austria 1995.
36. Graham C, **Vadas P**. Disseminated CMV infection with hypogammaglobulinemia and low CD4 count. American Academy of Allergy & Immunology Annual Meeting. New York, NY, U.S.A. 1995.
37. Graham C, Pruzanski W, Urowitz M, **Vadas P**. Induction of proinflammatory secretory phospholipase A2 (sPLA2) release by infusion of anti-CDw52 antibody (CAMPATH-1) in rheumatoid patients. American Academy of Allergy & Immunology Annual Meeting. New York, NY, U.S.A 1995.
38. Pruzanski W, **Vadas P**, de Beer FC. Interaction of proinflammatory phospholipase A2 (sPLA2) with atherogenic lipoproteins. Possible role in atherosclerosis in systemic lupus (SLE) IVth International Conference on Systemic Lupus Erythematosus - SLE Jerusalem, Israel 1995.
39. **Vadas P**, Pruzanski W, Koo Seen Lin M. Secretory Phospholipase A2 and Cox-2 expression by tracheobronchial smooth muscle cells. Cytokines and Adhesion Molecules in Lung Inflammation. Institut Pasteur Paris, France 1995.
40. Pruzanski W, de Beer FC, **Vadas P**. Interaction of proinflammatory phospholipase A2 (sPLA2) with the system of atherogenic lipoproteins. International Chemical Congress of the Pacific Basin Society. Honolulu, Hawaii, U.S.A 1995.

41. Kennedy B, Cromlish W, Payette P, Huang Z, Abdullah K, **Vadas P**, Pruzanski W, Mudgett J. Investigating the roles of the cytosolic and synovial fluid phospholipases. International Chemical Congress of the Pacific Basin Society. Honolulu, Hawaii, USA 1995.
42. **Vadas P**. Role of Phospholipase A2 in Inflammatory Disease. Keystone Symposia on Molecular & Cellular Biology on Lipid Second Messengers and Protein kinase C; Regulation, Structure, Function and role in human Disease. Taos, New Mexico. February 26-March 4, 1994.
43. Pruzanski W, deBeer FC, Stefanski E, **Vadas P**. Modulation of phospholipase A2 activity by atherogenic lipoprotein system. 9th International Conference on Prostaglandins and Related Compounds. Florence, Italy. June 6-10, 1994.
44. Pruzanski W, Kennedy B, **Vadas P**. Secretory nonpancreatic phospholipase A2 (sPLA2) expression in tracheobronchial smooth muscle cells (TBSM). 9th International Conference on Prostaglandins and Related Compounds. Florence, Italy. June 6-10, 1994.
45. Pruzanski W, de Beer FC, Kennedy B, Stefanski E, **Vadas P**. Modulation of synovial proinflammatory phospholipase A2 by acute phase reactants and microtubular disrupters. *Arthritis and Rheumatism* 37:R12, June 1994.
46. Pruzanski W, Katz A, Scott K, Browning J, **Vadas P**. Immunohistologic localization of secretory non-pancreatic phospholipase A2 (snp-PLA2) in sepsis and multiorgan failure (MOF). 4th Vienna Shock Forum, Vienna, Austria May 1993.
47. **Vadas P**, Pruzanski W. Cytokine-Induced Phospholipase A2 Expression in the Systemic Inflammatory Response Syndrome. 3rd International Conference on Lipid Mediators in Health and Disease. Jerusalem, Israel. 1993.
48. **Vadas P**, Demers B, McGeer A, Simor A, Schwartz B, Ferguson K, Grouix B. Serum Phospholipase A2 Levels Correlate with Disease severity in Group A streptococcal (GAS) disease. 4th Vienna Shock Forum, Vienna, Austria. May 1993.
49. **Vadas P**. Phospholipase A2 activity and septic shock. 8th FASEB Conference, Caxambu, Brazil. August 25-28, 1993.
50. Kennedy B, Culp S, Pruzanski W, **Vadas P**, Cromlish A. Eicosanoids and other bioactive lipids in cancer inflammation and radiation injury. 3rd International Conference. Washington D.C. October 13-16, 1993.
51. **Vadas P**, Pruzanski W. Regulation of secretory phospholipase A2 activity by C-reactive protein in septic shock. World Congress Inflammation '93, Vienna, Austria. October 10-15, 1993.
52. **Vadas P**, Pruzanski W. Phospholipase A2 in endotoxin Shock: Transcriptional regulation, substrate sequestration and biological roles. University of Bordeaux II. NATO Advanced Research Workshop. September 22-24, 1993.
53. Demers B, **Vadas P**, McGeer A, Simor A, Schwartz B, Ferguson K, Grouix B, Pruzanski W. Serum Phospholipase A2 Levels Correlate with Disease severity in Group A Streptococcal (GAS) Disease. Sixteenth Annual Conference on Shock, Santa Fe, New Mexico June 1993. *Circulatory Shock Suppl. 2*: 61 (1993).
54. **Vadas P**, Schouten D, Redelmeier D, Pruzanski W. A Comparison of Serum Phospholipase A2 Levels and Apache II Scores as Outcome Predictors in Septic Shock. Sixteenth Annual Conference on Shock, Santa Fe, June 1993. *Circ. Shock Supplement 2*: 61 (1993).
55. Edelson JD, **Vadas P**, Pruzanski W, Plumb J. Phospholipase A2 (PLA2) is cytotoxic to alveolar type II cells. American Thoracic Society, Miami, 1992.
56. **Vadas P**, Keystone J, Stefanski E, Scott K, Pruzanski W. Induction of secretory nonpancreatic phospholipase A2 in adults with malaria. Royal College of Physicians and Surgeons of Canada, Annual Meeting, Ottawa, 1992.
57. Demers B, Low D, McGeer A, Simor A, Schwartz B, Ferguson K, Grouix B, Pruzanski W, **Vadas, P**. Phospholipase A2(PLA2) levels in patients with group A streptococcal (GAS) disease. American Society for Microbiology, 32nd ICAAC, Anaheim, California, pp.371, Abstract 1564, 1992.
58. Pruzanski W, Greenwald RA, Street IP, Laliberte F, Stefanski E, **Vadas P**. Inhibition of enzymatic activity of phospholipases A2 by minocycline and doxycycline. 8th International Conference on Prostaglandins and Related Compounds, Montreal, July, 1992.
59. Ellies LG, Heersche JNM, Pruzanski W, **Vadas P**, Aubin JE. The role of phospholipase A2 in IL-1a induced inhibition of mineralization of osteoid formed by fetal rat calvarial cells. 8th International Conference on Prostaglandins and Related Compounds, Montreal, A133:Pp36, July, 1992.
60. **Vadas P**, Scott K, Stefanski E, Pruzanski W. Study of synovial fluid phospholipase A2 (PLA2) enzymatic activity and

immunoreactivity in inflammatory arthritides. 8th International Conference on Prostaglandins and Related Compounds, Montreal, A147:Pp 40, July, 1992.

61. Flood DA, Pruzanski W, Baughman RP, **Vadas P**. Extracellular phospholipase A2 activity in pleural fluids. Royal College of Physicians and Surgeons of Canada, Ottawa, September, 1992.
62. **Vadas P**, Pruzanski W. Signal Transduction: Phospholipase A2, Fatty Acids & Inflammation. Omega-3 Symposium - Omega-3 Fatty Acids Metabolism & Biological Effects. Sept. 15-19, 1992 Oslo, Norway.
63. Demers B, McGeer A, Low DE, Simor AE, Ferguson K, Grouix B, Pruzanski W, **Vadas P**. Correlation between Phospholipase A2 (PLA2) and Cytokine Levels Patients with Invasive Group A Streptococcal (GAS) Infections. 33rd ICAAC, New Orleans, Louisiana.
64. Pruzanski W and **Vadas P**. Controlling mechanisms of synthesis and release of secretory phospholipase A2 (PLA2). British Society for Rheumatology Ixth Annual General Meeting, July 21-24, 1992. London, England. Br. J. Rheumatol. 31(2):A1, P109, 1992.
65. Pruzanski W, Goulding NJ, Flower RJ, Urowitz MB, Gladman D, Goodman P, **Vadas P**. Correlation of phospholipase A2 (PLA2) and autoantibodies to lipocortin-1 with the activity of systemic lupus erythematosus (SLE). Lupus; 1:p.41, April 1992.
66. Edelson JD, Post M, **Vadas P**, Pruzanski W, Chan S. Surfactant protein A expression in phospholipase A2?induced lung injury. American Thoracic Society/American Lung Association, 1991.
67. Pruzanski W, **Vadas P**. Regulatory factors in the synthesis and release of phospholipase A2. FASEB Research Conference. Copper Mountain, Colorado, 1991.
68. **Vadas P**, Scott K, Stefanski E, Sternby B, Pruzanski W. Study of synovial fluid phospholipase A2 (PLA2) enzymatic activity and immunoreactivity in inflammatory arthritis. Am. College Rheumatol. 55th Annual Scientific Meeting. Boston, Mass. 1991.
69. **Vadas P**, Greenwald RA, Street, IT, Pruzanski W. Inhibition of synovial fluid phospholipase A2 activity by two tetracycline derivatives, minocycline and doxycycline. Am. College Rheumatol. 55th Annual Scientific Meeting. Boston, Mass. 1991.
70. Pruzanski W, Wloch M, Stefanski E, **Vadas P**. Modulatory activity of cytokines and polypeptide growth factors on the synthesis and release of phospholipase A2 (PLA2) from osteoblasts. International Congress on Inflammation, Rome, Italy, October, 1991.
71. **Vadas P**, Scott K, Stefanski E, Pruzanski W. Study of synovial fluid phospholipase A2 (PLA2) enzymatic activity and immunoreactivity in inflammatory arthritides. International Congress on Inflammation, Rome, Italy, October, 1991.
72. **Vadas P**, Pruzanski W, Farewell V. A predictive model for the clearance of circulating phospholipase A2 during septic shock in man. Second International Conference on Shock, Vienna, Austria, June 1991. Circulatory Shock 34: 78 (1991).
73. **Vadas P**, Pruzanski W. Plasma cortisol levels in patients with septic shock. Critical Care Medicine, Vol. 19, No. 2, 300-301, 1991.
74. Pruzanski W, **Vadas P**. The role of phospholipase A2 as a mediator of inflammation in septic shock. 2nd International Conference on Shock. Vienna, Austria, 1991. Circulatory Shock 34: 91 (1991).
75. Pruzanski W, Wloch M, Stefanski E, **Vadas P**. Modulatory activity of cytokines and polypeptide growth factors on the synthesis and release of phospholipase A2 from osteoblasts. Am. College Rheumatol. 55th Annual Scientific Meeting. Boston, Mass. 1991. Arth. Rheu. 34 (9):S118, 1991.
76. **Vadas P**, Pruzanski W, Stefanski E, Taylor TE, Molyneux M. Serum phospholipase A2 levels in severe falciparum malaria in children. International Congresses on Inflammation, Barcelona, Spain. June, 1990.
77. Pruzanski W, Stefanski E, Suffredini AF, Martich GD, Hoffman AGD, Wilmore DW, **Vadas, P**. Activation of extracellular phospholipase A2 following TNF induction by i.v. endotoxin administration to human volunteers. International Congresses on Inflammation, Barcelona, Spain. June, 1990.
78. Pruzanski W, **Vadas P**, Stefanski E, Wloch M, Bogoch E. The role of phospholipase A2 in the physiopathology of osteoarthritis. International Symposium on Osteoarthritis. Val-David, PQ. Oct. 1990.
79. Morton R, **Vadas P**, Stefanski E, Pruzanski, W, Pierratos A. Elevated phospholipase A2 (PLA2) activity in serum and

peritoneal fluid of patients undergoing continuous ambulatory peritoneal dialysis (CAPD). XITH International Congress of Nephrology, Tokyo, 1990.

80. Pruzanski W, Stefanski E, Suffredini AF, Martich GD, Hoffman AGD, Wilmore DW, **Vadas P**. Activation of extracellular phospholipase A2 following TNF induction by i.v. endotoxin administration to human volunteers. International Congress on Inflammation, Barcelona. A285, 1990.
81. Pruzanski W, Bogoch E, Wloch M, Stefanski E, **Vadas P**. Human articular chondrocytes synthesize and release phospholipase A2. American College of Rheumatology, 54th Annual Scientific Meeting, Seattle, Washington. 1990.
82. Pruzanski W, Bogoch E, Wloch M, Stefanski E, **Vadas P**. Activity of phospholipase A2 and muramidase in human cartilage. Differences between osteoarthritic and rheumatoid articular cartilage. American College of Rheumatology, 54th Annual Scientific Meeting. Seattle, Washington, 1990.
83. Johnson LK, Seilhamer JJ, Frank S, Lusi A, **Vadas P**, Pruzanski W. Synovial fluid phospholipase A2: Chromosomal localization with homologous genes may provide disease-related PLA2 diversity. American College of Rheumatology, 54th Annual Scientific Meeting. Seattle, Washington. 1990.
- 84. Vadas P**, Pruzanski W, Stefanski E. Effects of acyl group substitution and substrate presentation on synovial fluid phospholipase A2 activity in rheumatoid arthritis and osteoarthritis. XIth International Congress of Nephrology, Tokyo, 1990.
85. Pruzanski W, Stefanski E, Wilmore DW, Martich GD, Hoffman AGD, Suffredini A, **Vadas P**. Sequential activation of TNF-phospholipase A2 axis following i.v. endotoxin challenge in human volunteers. 1990 ASBMB/AAI.
86. Pruzanski W, Sherman ML, Kufe DW, **Vadas P**. Hyperphospholipasemia A2 following i.v. infusions of tumor necrosis factor in man. International Society of Hematology 23rd Congress, The American Society of Hematology 32nd Annual Meeting, Boston. 1990. Blood 76(suppl): 388a, 1990.
- 87. Vadas P**, Pruzanski W, Stefanski E, Taylor TE, Molyneux M. Serum phospholipase A2 levels in severe Falciparum malaria in children. ICOI Vol.1(1), 1990.
- 88. Vadas P**, Pruzanski W, Stefanski E. The influence of substrate presentation and acyl group substitution on rheumatoid and osteoarthritic synovial fluid phospholipase A2 activity. American College of Rheumatology, 54th Annual Scientific Meeting, Seattle, Washington. 1989. FASEB J: 4:A 2304, 1990.
89. Morton AR, Pierratos A, **Vadas P**, Stefanski E, Pruzanski W, Gorczynski R. Phospholipase A2 (PLA2) and interleukin-1 (IL-1) bioactivity in peritoneal dialysis patients. Perit. Dial. Int. 11 (Supp 1) 184, 1990.
90. Hoffman AGD, Martich GD, **Vadas P**, Pruzanski W, Seilhamer J, Suffredini AF. Elevation in serum phospholipase A2 in healthy humans given intravenous endotoxin after pretreatment with anti-inflammatory agents. Critical Care Medicine, Vol. 38, 340A Apr. 1990.
91. Ellies LG, Heersche JNM, **Vadas P**, Pruzanski W, Aubin JE. The stimulation by interleukin-1 of PGE2 and PLA2 release from fetal rat calvariae cells and its relationship to bone formation in vitro. ASBMR/ICCRH first joint meeting, 1989.
92. Morton AR, **Vadas P**, Stefanski E, Pruzanski W, Pierratos A. Increased levels of phospholipase A2 in renal failure patients. Am. Soc. Nephrol., Washington, December 1989.
93. Pruzanski W, **Vadas P**, Stefanski E, Seilhamer J, Johnson LK. Phospholipase A2 mediates inflammation in arthritis. 7th International Congress of Immunology, Berlin August 1989 A73:29, 1989.
94. Pruzanski W, Urowitz MB, Chang C, Bombardier C, **Vadas P**. Phospholipase A2(PLA2) in systemic lupus erythematosus. SLE. 1989.
95. Pruzanski W, **Vadas P**, Saito S, Stefanski E. Influence of a new pro-inflammatory enzyme-synovial fluid phospholipase A2 on the functions of human phagocytes. Am Rheum Assoc. 52nd Annual Scientific Meeting. May 23-28, 1988.
- 96. Vadas P**, Pruzanski W, Stefanski E. Comparative studies of human rheumatoid serum and synovial fluid phospholipase A2. Am. Rheum. Assoc. 52nd Annual Scientific Meeting, Houston, May 1988.
97. Pruzanski W, Lee P, Stefanski E, **Vadas P**. Hypophospholipasemia A2 in progressive systemic sclerosis (PSS). Am. Rheum. Assoc. 52nd Annual Scientific Meeting, Houston, May 1988.
98. Pruzanski W, Saito S, Stefanski E, **Vadas P**. Influence of a new proinflammatory enzyme-synovial fluid phospholipase

A2 on the functions of human phagocytes. Am. Rheum. Assoc. 52nd Annual Scientific Meeting, Houston May 1988.

99. **Vadas P**, Pruzanski W, Stefanski E, Ellies L, Aubin J. Interleukin-1-induced synthesis and secretion of extra-cellular phospholipase A2 from cultured bone-forming cells. International Conference "Lipoproteins and phospholipases", Paris, France, Sept. 1988.
100. Pruzanski W, **Vadas P**, Bogoch E, Stefanski E. Identification of phospholipase A2 (PLA2) in human articular cartilage. 4th International Conference "Therapeutic Control of Inflammatory Diseases". White Haven, Pen. Oct. 1988.
101. Pruzanski W, Saito S, Stefanski E, **Vadas P**. The modulation of human phagocytic function by rheumatoid synovial fluid phospholipase A2. 2nd International Conference on Leukotrienes and prostanoids in health and disease. Jerusalem, Israel, 1988.
102. **Vadas P**, Pruzanski W, Stefanski E, Ellies L, Aubin J. Interleukin-1-induced synthesis and secretion of extracellular phospholipase A2 from cultured bone forming cells. Bull. Soc. Chim. Biol. 53 (1):48 (1988).
103. **Vadas P**, Pruzanski W, Stefanski E, Johnson L, Seilhamer J, Mustard R, Bohnen J. Phospholipase A2 in acute bacterial peritonitis in man. Bull. Soc. Biol. 53 (1):48 (1988).
104. **Vadas P**, Pruzanski W, Stefanski E, Ellies L, Aubin J. Interleukin 1 induced synthesis and secretion of extracellular phospholipase A2 from cultured bone forming cells. Bull. Soc. Chim. Biol. 53 (1):48 (1988).
105. Pruzanski W, Keystone EC, Bombardier C, Snow KM, **Vadas P**. Phospholipase A2 correlates with disease activity in rheumatoid arthritis. ARA 51st Annual Meeting, Washington, June 1987. Abstract E87, 1987.
106. Pruzanski W, Urowitz MB, **Vadas P**. Activity of serum phospholipase A2 in systemic lupus erythematosus. American Rheumatism Association, 51st Annual Scientific Meeting, Washington D.C., 1987.
107. Pruzanski W, Silverman E, Laxer R, Albin-Cook K, Stefanski E, **Vadas P**. Correlation of phospholipase A2 level and disease activity in juvenile rheumatoid arthritis (JRA). ARA 51st. Annual Meeting, Washington 1987. Abstract E87, 1987.
108. **Vadas P**, Pruzanski W, Sos A, Melcher A, Jacobs H, Cheong T. Synthesis and secretion of soluble phospholipase A2 from cultured osteoblasts. ARA 51st Annual Meeting, Washington, June 1987. Abstract B51, 1987. Arthritis Rheumatism suppl 30:S56,1987.
109. **Vadas P**, Pruzanski W, Fornasier V, Kim J. Acute inflammation induced by intradermal and intra-articular injection of soluble phospholipase A2. Presented at the Annual Scientific Meeting of the American Rheumatism Association, New Orleans 1986.
110. **Vadas P**, Pruzanski W, Stefanski E, Asico W. Characterization and pharmacological inhibition of circulating phospholipase A2 in gram-negative septic shock with hyperphospholipasemia. Presented at the Annual Meeting of the Critical Care Society, Royal College of Physicians and Surgeons, Toronto 1986.
111. Stefanski E, **Vadas P**, Pruzanski W. Purification of soluble phospholipase A2 from rheumatoid synovial fluid. Presented at the American Rheumatism Association, Northeastern Regional Meeting, New York 1985.
112. **Vadas P**, Pruzanski W, Kim J, Jacobs H, Stefanski E. Studies of cellular sources proinflammatory enzyme phospholipase A2 in rheumatoid synovial fluid. Presented at the Annual Scientific Meeting of the American Rheumatism Association, Anaheim, 1985. Arth. Rheu. 28 (Suppl 4):590,1985.
113. Pruzanski W, **Vadas P**, Stefanski E, Urowitz M. Detection of proinflammatory enzyme phospholipase A2 in sera and synovial fluids in osteo and rheumatoid arthritis. Presented at the Royal College of Physicians and Surgeons, Montreal 1984.
114. **Vadas P**, Pruzanski W, Stefanski E. Identification and characterization of phospholipase A2 in synovial fluids in arthritis. Presented at the Annual Scientific Meeting of the American Rheumatism Association. Minneapolis. Arthritis Rheumatism Suppl. 4, 1984.
115. **Vadas P**. Role of phospholipase A2 in the pathogenesis of cardiopulmonary changes in septic shock. Presented at the Canadian Society for Clinical Investigation, Montreal, 1984. Clin. Invest. Med. 7:66, 1984.
116. **Vadas P**, Stefanski E, Pruzanski W. Detection and characterization of extracellular phospholipase A2 in inflammatory arthritis. Presented at The Canadian Society for Clinical Investigation, Montreal, 1984. Clin. Invest. Med. 7:86, 1984.

117. **Vadas P**, Hay JB. Extracellular phospholipase A2 from activated macrophages as a potential vasoactive mediator. Presented at the 4th International Congress of Immunology, Paris, 1980.
118. **Vadas P**, Hay JB. A blood flow mediator from chronic inflammatory cells. Presented at the 2nd World Congress of Microcirculation. *Microvasc. Res.* 17:123,1979.
119. Wasi S, **Vadas P**, Hunter W, Hay JB, Movat HZ. Kinetics of the production of plasminogen activator by cells emigrating from chronic granulomas. Presented at the 11th International Congress of Biochemistry, Toronto, 1979. Abstract 08-8-R112, 1979.
120. **Vadas P**, Hay JB. Hyperemia-inducing capacity of lymph and lymph cell products. 21st Annual Meeting of the Canadian Federation of Biological Societies Abstract 128, 1978.

Books Edited

1. **Vadas P**. Anaphylaxis: A Handbook for School Boards. Canadian School Boards Association. September 2001. **Consultant**.
2. Glaser K, **Vadas P** (Eds). Phospholipase A2 in Clinical Inflammation: Molecular approaches to Pathophysiology. CRC Press, Boca Raton, Florida, USA. 1995. **Editor**.
3. Pruzanski W, **Vadas P** (Eds). Novel Molecular Approaches to Anti-inflammatory Therapy. Birkhäuser Verlag, A.G. Basel. 1995. **Editor**.

Multimedia

1. www.vadas.net Practice Website.
2. www.vadasreport.net Newsletter in Allergy and Immunology.
3. petervadasmd.com Practice Website

Magazine

1. **Vadas P**. Help for Kids with Peanut Allergies. In OWL The Discovery Magazine for Kids. June 2003. **Contributor**.

Newsletter

1. **Vadas P**. Primary and secondary prevention of allergy. Anaphylaxis Network Newsletter. June 2000.

3. SUBMITTED PUBLICATIONS

F. Patents and Copyrights

| | |
|----------|---|
| 2007 Oct | Use of platelet activating factor acetylhydrolase as a biomarker for anaphylaxis., Patent, Applied, U.S. Patent application No. 60/984,105, United States, P Vadas |
| 1996 Jun | Synovial phospholipases, Patent, Granted, U.S. Patent application 426,899, United States, W. Pruzanski, LM Golub, P Vadas, RA Greenwalk, NS Ramamurthy, TF McNamara |
| 1991 Aug | Synovial phospholipases, Patent, Granted, European patent No. 88908529.6, LK Johnson, JJ Seilhamer, W Pruzanski, P Vadas, (Biotechnology Research Partners) |
| 1991 May | Synovial phospholipases, Patent, Granted, U.S. Patent application S.N. 231,865, United States, LK Johnson, JJ Seilhamer, W Pruzanski, P Vadas |

G. Presentations and Special Lectures

1. International

Invited Lectures and Presentations

- 2013 Feb 25 **Invited Speaker.** Fatal peanut anaphylaxis. American Academy of Allergy Asthma and Immunology. San Antonio, Texas, United States. Role of palet activating factor. Symposium on: Anaphylaxis: Novel Mechanisms and Therapeutic Implications.
- 2012 Mar 1 **Lecturer.** Epinephrine phosphorylates the PAF receptor in human vascular smooth muscle cells. National Peanut Board , Orlando , FLA. Florida, United States.
- 2010 Jun **Invited Lecturer.** Plenary Lecture: Regulation of IgE and Anaphylaxis. European Academy of Allergy and Immunology. London, United Kingdom. Presenter(s): **Peter Vadas.**
- 2010 Mar **Invited Lecturer.** Symposium Lecture: Mechanisms of Anaphylaxis. American Academy of Allergy, Asthma and Immunology. New Orleans, Louisiana, United States. Presenter(s): **Peter Vadas.**
- 2009 Mar **Invited Speaker.** Concurrent histamine and PAF blockade in peanut allergic mice. Scientific Advisory Committee, National Peanut Board. Atlanta, Georgia, United States.
- 2008 Sep **Invited Speaker.** Personal respiratory protection in the post-SARS era. Biomedical Advanced Research and Development Authority, Department of Health and Human Services. Washington, District of Columbia, United States.
- 2007 Nov **Invited Lecturer.** Food Allergies: Diagnosis, Future Pathways of Treatment and Limitations of Current Therapies. International Conference on Food Allergy and Consumer Protection. Health Canada and The Canadian Food Inspection Agency. Montreal.
- 2007 Mar Epidemiology of food allergies among children of peanut farmers. National Peanut Board. San Diego.
- 2003 Mar **Invited Lecturer.** Novel Approaches to Treatment of Anaphylaxis Based on Pathophysiologic Mechanisms. AAAAI Annual Meeting. Denver.
- 2003 Mar **Invited Lecturer.** PAF Acetylhydrolase Deficiency Predisposes to Fatal Anaphylaxis. AAAAI Annual Meeting. Denver.
- 2001 Mar **Co-Chair.** Mechanisms and Prevention of Anaphylaxis. Mini-Symposium. AAAAI Conference. New Orleans.
- 2001 Mar **Co-Moderator.** Unusual Causes of Anaphylaxis: Is Mastocytosis a Risk Factor? AAAAI Conference. New Orleans. Workshop.
- 2001 Mar **Co-Chair.** Anaphylactic Reactions for Foods. AAAAI Conference. New Orleans. Seminar.
- 2000 Dec **Invited Lecturer.** PAF-AH Deficiency Predisposes to Fatal Peanut Anaphylaxis. American Peanut Council Annual General Meeting. Alexandria, Virginia.
- 1999 **Invited Lecturer.** Study of the allergenicity of plant protein hydrolysates. AAAAI Annual Meeting. Orlando, Florida. Presenter(s): Tsai E, Yeung J, Gold M, Sussman G, Perelman B, **Vadas P.**
- 1999 **Invited Lecturer.** Maternal dietary peanut protein secreted in breast milk during lactation. The Peanut Foundation Annual General Meeting. Washington, District of Columbia.
- 1999 **Invited Lecturer.** Trace exposures causing anaphylactic deaths. Thresholds for Allergenic Foods: How much is too much? Hilton Head Island, South Carolina.
- 1995 **Invited Lecturer.** The effect of lipid peroxidation on human secretory phospholipase A2-mediated degradation of cell membranes. Fifth Vienna Shock Forum. Vienna, Austria.
- 1995 **Invited Lecturer.** Phospholipase A2 in sepsis and septic shock. Abdominal Sepsis. University of Berne. Switzerland.
- 1994 **Invited Lecturer.** Role of phospholipase A2 in inflammatory disease. Keystone Symposia on molecular and cellular biology on lipid second messengers and protein kinase regulation, structure, function and role

in human disease. Taos, New Mexico.

- 1994 **Invited Lecturer.** Cytokines, phospholipase A2 and acute phase proteins. An interactive network in septic shock. Seventeenth Annual Conference on Shock. Big Sky, Montana.
- 1993 **Invited Lecturer.** Group II PLA2 expression and pathogenesis of systemic inflammatory reactions and associated multi-system organ failure. 4th Shock Forum. Vienna, Austria.
- 1993 **Invited Lecturer.** Group II phospholipase A2 expression and the pathogenesis of septic shock. Brazilian FASEB Meeting. Caxambu, Brazil.
- 1993 **Invited Lecturer.** A Comparison of serum phospholipase A2 levels and APACHE II scores as outcome predictors in septic shock. 4th Shock Forum. Vienna, Austria.
- 1993 **Invited Lecturer.** The functional relationship between PLA2 and pentraxins in septic shock. Cytokines and lipid mediators in regulation of cell function. FASEB Summer Research Conferences. Copper Mountain, Colorado.
- 1993 **Invited Lecturer.** Group II phospholipase expression and the pathogenesis of septic shock. NATO Advanced Research Workshop, University of Bordeaux II. France.
- 1993 **Invited Lecturer.** Cytokine-induced phospholipase A2 expression in the systemic inflammatory response syndrome. 3rd International Conference on Lipid Mediators in Health & Disease. Jerusalem, Israel.
- 1992 **Invited Lecturer.** Omega-3 fatty acids. Metabolism and biological effects. Plenary lecture: Signal transduction: Phospholipases A2, fatty acids and inflammation. Oslo, Norway.
- 1992 **Invited Lecturer.** Phospholipase A2-basic and clinical aspects in inflammatory disease. International Symposium on PLA2. Ulm, Germany.
- 1992 **Invited Lecturer.** Intracellular signal transduction pathways and cytokine-induced expression of group II PLA2. Ulm, Germany.
- 1991 **Invited Lecturer.** Biogen. Cambridge, Massachusetts.
- 1991 **Invited Lecturer.** Brigham and Women's Hospital, Division of Surgical Metabolism and Nutrition, Harvard University. Boston, Massachusetts.
- 1991 **Invited Lecturer.** Cytokine and lipid mediators as regulators of cell function. FASEB Conference. Copper Mountain, Colorado.
- 1990 **Invited Lecturer.** Sterling Drugs. Malvern, Pennsylvania.
- 1990 **Invited Lecturer.** Eli Lilly Pharmaceuticals. Indianapolis, Indiana.
- 1989 **Invited Lecturer.** Biochemical Pharmacology Discussion Group, New York Academy of Science. New York.
- 1989 **Invited Lecturer.** Hoffman-La Roche. Ridgefield, Connecticut.
- 1989 **Invited Lecturer.** Wyeth-Ayerst. Princeton, New Jersey.
- 1989 **Invited Lecturer.** National Institutes of Health, Critical Care Section. Bethesda, Maryland.
- Invited Speaker.** Scientific Advisory Board. National Peanut Board. Atlanta, Georgia, United States.

2. National

Invited Lectures and Presentations

- 2012 Jan 24 Hereditary angioedema. HAE advisory board.
- 2011 Nov 19 Mechanisms of anaphylaxis . Review of auto-injector devices. Sanofi-Aventis Anaphylaxis Advisory Forum. Canada.

- 2011 Sep 21 Hereditary angiodema. Berinert Advisory Board: HAE Council.
- 2009 Oct **Invited Lecturer.** Symposium Lecture: Anaphylaxis: New Research and Clinical Paradigms. Canadian Society of Allergy and Clinical Immunology. Halifax, Nova Scotia, Canada. Presenter(s): **Peter Vadas**.
- 2009 Feb **Invited Lecturer.** Peanut-induced anaphylaxis: Epidemiology, manifestations and management. Canadian Peanut Bureau. Canada.
- 2000 **Invited Lecturer.** What's New in Anaphylaxis? Canadian society of Allergy and Clinical Immunology. Annual Scientific Meeting. Toronto.
- 1994 **Invited Lecturer.** Membrane perturbation is a requirement for phospholipase A2 induced cytolysis. Merck Frosst Centre for Therapeutic Research. Montreal, Quebec.
- 1991 **Invited Lecturer.** Merck Frosst Institute of Therapeutic Research. Montreal, Quebec.
- 1990 **Invited Lecturer.** Merck Frosst. Montreal, Quebec.
- 1989 **Invited Lecturer.** Merck Frosst Laboratories. Quebec.

Media Appearances

- 2001 Dec **Invited Speaker.** Development of a new monoclonal anti-IgE vaccine for peanut anaphylaxis. Interviewer: Dave Arnold. OR77 EDMONTON. Edmonton, Alberta, Canada.
- 2001 Dec Development of a new monoclonal anti-IgE vaccine for peanut anaphylaxis. QR77 EDMONTON. Interview with Dave Arnold.
- 2001 Nov Reason for increased worldwide incidence of allergies. GLOBAL TV. Montreal. Interview.
- 2001 Nov **Invited Speaker.** Reason for increased worldwide incidence of allergies. GLOBAL TV. MONTREAL, Quebec, Canada.
- 1996 Apr 3 CJAD RADIO - MONTREAL. Melanie King interviews Dr. **Vadas** on peanut allergies.
- 1996 Jan 2 **Invited Speaker.** Anaphylaxis. Interviewer: John McComb. CKNW RADIO. Vancouver, British Columbia, Canada.
- 1995 Aug 9 CKNW VANCOUVER - RADIO. Rose Mair interviews Dr. **Vadas** on the Anaphylaxis Clinic.
- 1994 Jul 20 When death lurks in a label. THE GLOBE & MAIL, National News.

3. Provincial / Regional

Invited Lectures and Presentations

- 2003 Feb **Invited Lecturer.** Allergic Rhinitis. Chinese Medical Association. Collingwood.
- 2001 Nov **Invited Lecturer.** Factors Predisposing to Life-Threatening Allergies. Department of Medicine, Scarborough Centenary Hospital. Scarborough.

Media Appearances

- 1995 Dec 20 **Invited Speaker.** Food allergies a concern at Christmas. THE SAULT STAR.
- 1995 Aug 9 **Invited Speaker.** Anaphylaxis Clinic. Interviewer: Rose Mair. 680 NEWS RADIO. Toronto, Ontario, Canada.

4. Local

Invited Lectures and Presentations

- 2012 May 2 Graded oral challenge to peanut: logistics and safety. St. Michael's Hospital , Research Ethics Board. Toronto, Ontario, Canada.
- 2012** **Lecturer.** Graded oral challenges to peanut. Logistics and Safety. St. Michael Hospital. Research Ethics Board. Toronto, Ontario, Canada.
- 2009 May **Invited Speaker.** Anaphylaxis: What is the risk? Canadian Life Insurance Medical Officers Association. Toronto, Canada.
- 2009 Apr **Invited Lecturer.** Hereditary Angioedema: Management in pregnancy. Obstetric and Gynecology Rounds. Mount Sinai Hospital. Toronto, Canada.
- 2009 Apr **Invited Lecturer.** Xolair: The St. Michael's Hospital Experience. Respiriology Rounds. Toronto Western Hospital. Toronto, Canada.
- 2009 **Lecturer.** Investigation and Management of Anaphylaxis. St. Michael's Hospital.
- 2008 Dec **Invited Lecturer.** Idiopathic anaphylaxis ... not anymore. St. Michael's Hospital Grand Rounds. Toronto, Canada.
- 2008 Feb **Invited Lecturer.** Food allergies. University half day – Department of Gastroenterology. St. Michael's Hospital. Toronto, Ontario, Canada.
- 2007 Apr** **Vadas P.** Monoclonal anti-IgE vaccine in treatment of asthma and peanut allergy. Scarborough Centenary Hospital.
- 2007 Feb **Invited Lecturer.** Penicillin Allergy and Skin Testing. Noon Rounds, St. Michael's Hospital.
- 2006 Nov **Invited Lecturer.** Anaphylaxis. Allergy & Immunology Residents Rounds, St. Michael's Hospital.
- 2006 Aug **Invited Lecturer.** Anaphylaxis. Department of Medicine Summer Emergency Lecture Series, St. Michael's Hospital.
- 2006 Jun **Invited Lecturer.** Anaphylaxis. Department of Medicine Noon Rounds, St. Michael's Hospital.
- 2006 May **Invited Lecturer.** Anaphylaxis. Department of Medicine Noon Rounds, St. Michael's Hospital.
- 2006 Feb **Invited Lecturer.** Penicillin Allergy and Skin Testing. Noon Rounds, St. Michael's Hospital.
- 2005 May **Invited Lecturer.** Anaphylaxis. Noon Rounds, St. Michael's Hospital Step-Up Unit.
- 2005 May **Invited Lecturer.** Frontiers in allergy & asthma: emerging issues and their implications. Allergy Expo Canada. Toronto.
- 2005 May **Invited Lecturer.** New treatment options for food allergies. Allergy Expo Canada. Toronto.
- 2005 Feb **Invited Lecturer.** Health Effects of Moulds: The Proven, the Suspect and the Unknown. Grand Rounds, St. Michael's Hospital.
- 2004 Oct **Invited Lecturer.** Anaphylaxis: Mechanism-Based Management. University Health Network Emergency Conference. Toronto.
- 2004 May **Invited Lecturer.** Anaphylaxis. Noon Rounds, St. Michael's Hospital.
- 2004 May **Invited Lecturer.** Drug Allergies and Drug Desensitization in Patients with Cystic Fibrosis. Grand Rounds, St. Michael's Hospital. Presenter(s): **Vadas P**, Tullis E.
- 2004 Apr **Invited Lecturer.** New Advances: Allergy and Anaphylaxis. Allergy Update 2004. AAISO. Toronto.
- 2004 Mar **Invited Lecturer.** Anaphylaxis. Noon Rounds, St. Michael's Hospital.
- 2004 Jan **Invited Lecturer.** Anaphylaxis in the Emergency Department. City-Wide Emergency Grand Rounds, Mount Sinai Hospital.

- 2004 **Invited Lecturer.** Life-threatening allergies and asthma in the 21st century. St. Michael's Hospital Foundation.
- 2004 **Invited Lecturer.** New advances in management of peanut allergy developed at St. Michael's Hospital. St. Michael's Hospital Foundation.
- 2003 Dec **Invited Lecturer.** Clinical Manifestations of Mould Exposure. Environmental Health Clinic, Sunnybrook & Women's College Health Sciences Centre.
- 2003 Nov **Invited Lecturer.** A New Advancement in Intravenous Immune Globulin Therapy. Department of Pediatric Laboratory Medicine Rounds, The Hospital for Sick Children.
- 2003 Oct **Invited Lecturer.** Immunomodulation: The Good, The Bad and The Ugly. Grand Rounds, St. Michael's Hospital.
- 2003 Oct **Invited Lecturer.** Food Allergy: Diagnosis and Management. Family and Community Medicine, Faculty of Medicine, University of Toronto.
- 2003 Oct **Invited Lecturer.** New Approaches in the Diagnosis and Management of Urticaria and Angioedema. Family and Community Medicine, Faculty of Medicine, University of Toronto.
- 2003 Oct **Invited Lecturer.** Allergen Immunotherapy: The First Century and Beyond. Primary Care Today: Therapeutic Update. Family and Community Medicine, Faculty of Medicine, University of Toronto.
- 2003 Mar **Invited Lecturer.** Overview of Allergens, Reactions...What Food Manufacturers Should Know. Ontario Food Protection Association Spring Technical Meeting. Toronto. Keynote Address.
- 2003 Feb **Invited Lecturer.** Management and Prevention of Anaphylaxis. Step Up Unit Lecture Series, St. Michael's Hospital.
- 2002 Nov **Invited Lecturer.** Future Therapies for Anaphylaxis. Toronto Anaphylaxis Education Group (Laurie Harada Co-ordinator). Toronto.
- 2002 May **Invited Lecturer.** Immune Deficiency. Cardiology Seminar, St. Michael's Hospital.
- 2001 Nov **Invited Lecturer.** The Connection Between Upper and Lower Airway Inflammation. Toronto ENT Physicians, Rosewater Supper Club. Toronto.
- 2001 Jul **Invited Lecturer.** Anaphylaxis (and other Drug Reactions). Summer Emergency Lecture Series, St. Michael's Hospital.
- 2001 May **Invited Lecturer.** Highlights of the AAAAI – Anaphylaxis. ATS & AAAAI Update, Vaughan Estates, Sunnybrook. Toronto.
- 2001 Mar **Invited Lecturer.** PAF-AH Deficiency Predisposes to Fatal Peanut Anaphylaxis. Grand Rounds, St. Michael's Hospital.
- 2001 Mar **Invited Lecturer.** Platelet Activating Factor Acetylhydrolase Deficiency and Its Relationship to Fatal Anaphylaxis. Medical Grand Rounds, St. Michael's Hospital.
- 2000 Sep **Invited Lecturer.** The Long and Winding Road: The Story of Phospholipase A2 and Septic Shock. Grand Rounds, St. Michael's Hospital.
- 2000 Sep **Invited Lecturer.** Allergy Treatment Options. Journal Club of Chinatown Physicians (Sponsor: Aventis Pharma). Toronto.
- 2000 **Invited Lecturer.** Anaphylaxis: Prevention and Management. Allergy Update 2000 17th Annual Symposium. AAISO & the Ontario Medical Association. Toronto.
- 2000 **Invited Lecturer.** Allergy treatment options. The Journal Club of Chinatown Physicians. Toronto.
- 2000 **Invited Lecturer.** Living with Anaphylaxis: A Panel Discussion. Anaphylaxis Network of Canada. Toronto. Presenter(s): Gold M, **Vadas P.**
- 2000 **Invited Lecturer.** Prevention of anaphylaxis in the office setting. CME Lecture. Toronto. (Continuing Education).

- 2000 **Invited Lecturer.** Prevention and Management of Anaphylaxis in the Office Setting. AstraZeneca Canada Inc. Toronto.
- 1999 Sep **Invited Lecturer.** Detection of peanut protein in breast milk of lactating women. Grand Rounds, St. Michael's Hospital.
- 1999 **Invited Lecturer.** Occult sensitisation of anaphylactically sensitive children. Hospital for Sick Children, Division of Immunology. Toronto.
- 1999 **Invited Lecturer.** Allergen desensitization: does it work? Saturday At the University – University of Toronto. Toronto.
- 1999 **Invited Lecturer.** Anaphylaxis: is my office prepared? Saturday At the University – University of Toronto. Toronto.
- 1999 **Invited Lecturer.** Acute and chronic urticaria. Saturday At the University – University of Toronto. Toronto.
- 1999 **Invited Lecturer.** Adult and congenital immune deficiencies. Core Curriculum Lecture, St. Michael's Hospital.
- 1997 **Invited Lecturer.** Nothing to sneeze at – the rundown on rhinitis. Toronto Public Allergy Forum, Lexicomm Communications Ltd. Toronto, Canada.
- 1997 **Invited Lecturer.** Research Update. The Hospital for Sick Children, Division of Immunology and Allergy.
- 1997 **Invited Lecturer.** Indoor allergies and pharmaceutical care. Schering Canada Inc. Toronto, Canada.
- 1996 **Invited Lecturer.** Anaphylaxis. Ontario Medical Association, Section on Allergy and Clinical Immunology. Toronto, Canada.
- 1995 **Invited Lecturer.** Introduction to anaphylaxis. Wellesley Hospital Lecture to the Public.
- 1991 **Invited Lecturer.** Governor's Circle Lecture, Wellesley Hospital Research Institute. Toronto.

Media Appearances

- 2000 Oct GLOBAL NEWS. Interview (with Steve Kassar) Undeclared peanut protein in imported chocolate bars.
- 2000 Oct CBC RADIO: "Metro Morning". Interview (with Andy Barry) Undeclared peanut protein in imported chocolate bars.
- 2000 Oct **Invited Speaker.** Undeclared peanut protein in imported. Interviewer: Andy Barry. CBC RADIO. Toronto, Ontario, Canada.
- 2000 Oct **Invited Speaker.** Undeclared peanut protein in imported chocolate bars. Interviewer: Steve Kassar. GLOBAL NEWS. Toronto, Ontario, Canada.
- 2000 Sep **Invited Speaker.** Peanut allergy in schools. Interviewer: Andy Barry. CBC RADIO "METRO MORNING" with Kim Curran, Media Works. Toronto, Ontario, Canada.
- 2000 Sep CBC RADIO: "Metro Morning". Interview (with Andy Barry) Peanut allergy in schools. With Kim Curran, MediaWorks.
- 1995 Dec 18 **Invited Speaker.** Yule foods can be peril for allergies, MD's warn. Interviewer: Leslie Papp. TORONTO STAR. Toronto, Ontario, Canada.
- 1994 Aug 11 CITY TV, City Pulse News at 6. Judy Haladay interviews Dr. **Peter Vadas** on the effects of hayfever. (2 Min.).
- 1994 Jul 28 GLOBAL NEWS AT NOON. Loretta Sullivan interviews Dr. **Peter Vadas** live on-the-air about the Anaphylaxis Clinic at The Wellesley Hospital.
- 1994 Jul 28 CHUM FM - RADIO. Toronto. Dan Turner interviews Dr. **Vadas** about the Anaphylaxis Clinic.
- 1994 Jul 28 680 NEWS - RADIO. Carolyn Heldman interviews Dr. **Vadas**.

- 1994 Jul 25 LIGHT 97.3 - RADIO. Mark Henderson interviews Dr.**Peter Vadas** on the Anaphylaxis Clinic.
- 1994 Jul 25 CISS FM 92.5 - RADIO, Health Files. Tim Abray interviews Dr.**Vadas** on the Anaphylaxis Clinic.
- 1994 Jul 1 **Speaker.** CFRB AM - RADIO, The World Today. Debra Hoerst interviews Dr.**Peter Vadas** on the Wellesley Hospital's Regional Anaphylaxis Clinic.

Presentations and Special Lectures

- 1999 **Presenter.** 1. Allergen desensitization: does it work? 2. Anaphylaxis: is my office prepared? 3. Acute and chronic urticaria. Saturday At the University – University of Toronto.
- 1999 **Presenter.** Adult and congenital immune deficiencies. St. Michael's Hospital Core Curriculum Lecture.

Symposia

- 2002 **Co-Chair.** Allergy Update 2002: A Special Symposium in Allergy and Clinical Immunology for the Practicing Physician and Allied Health Professional. Toronto.
- 1999 **Chair.** International Symposium on Anaphylaxis. Toronto.

5. Other

Invited Lectures and Presentations

- 2007 May **Invited Lecturer.** Practical Approaches to Management of Anaphylaxis and Food Allergies. Schering-Plough.
- 2005 May **Invited Lecturer.** Biology of IgE and concept of an anti-IgE vaccine. Toronto Anaphylaxis Education Group.
- 2005 May **Invited Lecturer.** Results from the TNX trial. Toronto Anaphylaxis Education Group.
- 2005 May **Invited Lecturer.** RASTS and graded oral challenges. Toronto Anaphylaxis Education Group.
- 2005 **Invited Lecturer.** Allergy & Patanol. Alcon. Audience: Toronto Ophthalmologists. (Continuing Education).
- 2001 Mar **Invited Lecturer.** Anaphylaxis Links to Research – Links to Treatment. AAIA Conference.
- 1999 Feb **Invited Lecturer.** Food allergies and anaphylaxis. St. Michael's Family Practice Unit. Hoechst Marion Roussel Canada Inc.
- 1998 Jun **Invited Lecturer.** Challenges in allergy management – new treatment options. Hoechst Marion Roussel Canada Inc.
- 1998 May **Invited Lecturer.** Challenges in allergy management – new treatment options. Hoechst Marion Roussel Canada Inc.
- 1997 Oct **Invited Lecturer.** Challenges in allergy management – new treatment options. Hoechst Marion Roussel Canada Inc.
- 1997 Aug **Invited Lecturer.** Challenges in allergy management – new treatment options. Hoechst Marion Roussel Canada Inc.
- 1997 **Invited Lecturer.** Educational Forum, Anaphylaxis Network of Canada.

Media Appearances

- 2007 Interview with Claire Gagne. "The Stingers: Risks, reactions and protecting yourself" from wasp or bee. ALLERGIC LIVING.
- 2007 Interview with Janet French. "Doubled Trouble: Coping with multiple allergies.". ALLERGIC LIVING.

2005 Apr People more sensitive to allergy triggers: study. Response to Malcolm Law study published in British Medical Journal. CTV.ca. CTV News Staff Interview.

2004 Sep Interview with Ian Macleod. Bill 3 and protection of children with life-threatening allergies. OTTAWA CITIZEN.

2004 Aug Interview with Helen Henderson. New advances and research in life-threatening allergies. TORONTO STAR.

2004 Feb Interview with Moira MacDonald. Development of genetically modified foods as a treatment for food allergy. NATIONAL POST.

2004 Jan Interview with Karen Palmer. Peanut and other food allergies and research on activated charcoal. TORONTO STAR.

2002 Oct Interview with Carey Goldberg. New therapeutic approaches to the treatment of food allergies. THE BOSTON GLOBE.

2002 Oct The reason for the increased prevalence of allergies, the hygiene hypothesis, and the role of endotoxin in modulating allergies. CBC THE NATIONAL. Interview with Maureen Taylor.

2002 Feb Breast milk can carry peanut protein. Story by Terry Murray, The Medical Post, reprinted in Reader's Digest. READER'S DIGEST.

2001 Nov Study Panel: Asthma. FACE-TO-FACE The Global Chapter.

2001 Nov Allergic disease. HEALTH ON THE LINE, Discovery Health Network.

2001 Apr In response to JAMA publication of "Detection of peanut allergens in breast milk of lactating women". National Post, Globe and Mail, The Toronto Star, Canadian Press, Associated Press, Reuters, CBC, CTV, City-TV, Global TV, BBC, CNN, WEB MD, Chicago Post, L.A. Times, Voice of America, Time Magazine.

2001 Feb Allergies and Anaphylaxis. CTV, The Chat Room.

2001 Feb Remission of Peanut Allergies. CBC: National News.

2001 Jan A tempest in a taco shell. (Contributor to article by Michael Fumento). THE NATIONAL POST.

2000 Oct Peanut protein May Be Passed Through Breast Milk: Landmark Canadian study finds mothers' milk possible source of peanut allergy in children. (Contributor to article by Suzi Martin-Cusimano). THE CHRONICLE OF SKIN & ALLERGY.

2000 Oct WEB MD CANADA. Interview (with Gillian Wansborough) Undeclared peanut protein in imported chocolate bars.

2000 Oct Chocolate bars pulled from stores. (Contributor to article by Tanya Talaga, Toronto Star Medical Reporter). THE TORONTO STAR.

2000 Sep **Presenter.** Optimal Prevention and Management of Anaphylaxis: Antihistamine no substitute for epinephrine in the first-line treatment of anaphylaxis. (Suzi Martin-Cusimano. A review of Allergy 2000 Update). THE CHRONICLE OF SKIN & ALLERGY.

2000 Jun Cited in: Allergy Update Symposium: Immunotherapy, anaphylaxis, and contact dermatitis among topics addressed. ONTARIO MEDICAL REVIEW. Pages 31 – 35.

1998 May 9 GLOBAL TELEVISION. Program on seasonal and life-threatening allergies with comments from Dr. **Vadas**.

1996 Jun "Eat, drink and be wary", feature story on food allergies with comments from Drs. Peter Vadas and Gord Sussman. CHATELAINE. June 1996 edition.

1996 May 14 DISCOVERY CHANNEL. Feature story on immunologist Dr. **Peter Vadas** and allergy season.

1996 Mar 25 CFRB RADIO/"THE WORLD AT NOON". Deborah Hearst interviews Dr. **Peter Vadas** on peanut allergies.

1996 Mar Nora Underwood, Dr. Peter Vadas interviewed on new treatments for anaphylaxis. CHATELAINE: March

- 1996 edition (tba).
- 1995 Dec 20 "Food allergies a concern at Christmas". THE SAULT STAR.
- 1995 Dec 18 Leslie Papp, "Yule foods can be peril for allergies, MD's warn". TORONTO STAR.
- 1995 Dec 18 CFRB RADIO. Dr. Peter Vadas interviewed on increase in anaphylaxis during the holidays.
- 1995 Dec 17 Elison Chu, "Risk of severe food allergies increases during holiday season". MING PAO, Chinese Community Newspaper.
- 1994 Aug 13 Marilyn Dunlop writes about the opening of the Anaphylaxis Clinic. THE TORONTO STAR, New in Medicine (Life). Page K2.
- 1994 Jul Wellesley Hospital opens Regional Anaphylaxis Clinic. ONTARIO MEDICAL REVIEW. Page 69.
- 1994 Jul Latenews. ONTARIO MEDICINE. Page 4.
- 1994 Allergy Clinic at The Wellesley Hospital. THE TORONTO VOICE, Community Publication. Summer 1994, Volume 10, Pg. 20.
- Life-Threatening Allergies. PLANET PARENT. Toronto

H. Research Supervision

1. Multilevel Education

- 2012 Mar Dr. Cindy Bauer, Clinical Fellow.,USA
- 2011 Jul Dr.Thatchai Kampitak., Clinical Fellow, Thailand
- 2011 Jun Dr. Cindy Bauer ,Clinical Fellow, USA

2. Undergraduate Education

- 2012 Adam Deverett. *Determinants of severe anaphylaxis.*
- 2012 Ella Pesach. *Determinants of severe anaphylaxis.*
- 2012 Akshdeep Bhatia. *Postural Orthostatic Tachycardia Syndrome, Ehlers Danlos Syndrome and Mast Cell Activation Syndrome.*
- 2012 Akshay Lobo. *Postural Orthostatic Tachycardia Syndrome, Ehlers Danlos Syndrome and Mast Cell Activation Syndrome.*
- 2012 Areej Adil. *PAF-AH and low density lipoprotein complex formation.*
- 2012 Christine Ng. *Retrospective study of anaphylaxis fatalities in Ontario.*

3. Graduate Education

- 1998 - 2000 **Primary Supervisor**, Addic Brillon. MSc.

4. Postgraduate MD

- 2011 July Dr. Amanda Jagdis . Core Program, Acquisition of peanut allergy in children of peanut farmers.
- 2012 July Dr. Christine Song. Core Program Active secretion of peanut protein in saliva.

5. Other

2012 Feb Collaborator(s): Dr. Amanda Jagdis PGY3.
2011 Nov Collaborator(s): Dr. Tatchai Kampitak Clinical Fellow.

I. Creative Professional Activities

1. Contributions to the Development of Professional Practices (2013)

2013 Jun 15 Viropharma (Cinryze) Toronto, Member, Advisory Board 2013 May 15 Pfizer Toronto, Anaphylaxis and food allergies.
2013 Jan 22 Sanofi Canada, Update on Anaphylaxis.
2012 Dec 1 Member of Allergy Advisory Board, Regional Allergic Advisory Board, Takeda Canada Toronto
2012 Dec 7 Sanofi (Allerject) Toronto, Member Advisory Board.

2. Exemplary Professional Practice (2013)

2013 President's Review Report, Division of Allergy and Clinical Immunology St. Michael Hospital
2013 Canadian Health Family Program Toronto, Food Allergies and Anaphylaxis
2013 Toronto Endocrine Society, Insulin Hypersensitivity and desensitization.
2013 Medical Inspector and Expert Witness, College of Physicians and Surgeons of Ontario
2013 Consultant to Department of Medical Imaging, Treatment of Contrast Media Reactions St. Michael's Hospital
2013 Examination Committee, Allergy and Clinical Immunology Examination Committee, for Hospital for Sick Children.